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Abstract
The Development of a Rapid Immunosensor for the
Quantiﬁcation of Insulin
CC. Van Dyk
Department of Mechanical and Mechatronic Engineering,
University of Stellenbosch,
Private Bag X1, Matieland 7602, South Africa.
Thesis: MEng (Mech)
April 2019
Diabetes is a serious, chronic disease that occurs when the pancreas fails
to produce enough insulin (in type 1 diabetes), or when the body cannot
use the insulin, produced by the pancreas, eﬀectively (in type 2 diabetes).
Measuring and diagnosing type 2 diabetes is currently performed by conven-
tional immunoassay techniques which require sophisticated equipment, are ex-
tremely time consuming and expensive. This increases the need for a rapid
point-of-care device which will enable diabetic patients to monitor insulin lev-
els on a more regular basis and help with the compliance in following strict
diets and also improve overall medical healthcare. Immunosensors are com-
pact, analytical devices that detect and measure a speciﬁc antigen (e.g. pro-
teins) by using biological receptors, such as antibodies, and speciﬁc trans-
ducing mechanisms to generate a measurable signal. The Organic Electro-
chemical Transistor (OECT) has been developed as a promising alternative to
conventional immunoassays. The electrochemical signal produced by OECT-
based immunosensors is generated as a result of the antigen-antibody binding.
OECT-based immunosensors present real-time, rapid results and exhibit high
sensitivity and selectivity towards the antigen. In this project an unique inex-
pensive rapid OECT-based immunosensor was developed, capable of detecting
and quantitatively measuring insulin. As part of the research a thorough lit-
erature review and background study was undertaken.
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Uittreksel
Die Ontwikkeling van 'n Sorgtoestel om Insulien Vinnig
te Kwantiﬁseer
(The Development of a Rapid Immunosensor for the Quantiﬁcation of Insulin)
CC. Van Dyk
Departement Meganiese en Megatroniese Ingenieurswese,
Universiteit van Stellenbosch,
Privaatsak X1, Matieland 7602, Suid Afrika.
Tesis: MIng (Meg)
April 2019
Diabetes is 'n ernstige, chroniese siekte wat voorkom wanneer die pankreas
nie genoeg insulien produseer nie (in die geval van tipe 1-diabetes), of wanneer
die liggaam nie die insulien wat deur die pankreas geproduseer word, eﬀektief
gebruik nie (in die geval van tipe 2-diabetes). Die meting en diagnose van
tipe 2-diabetes word tans uitgevoer deur konvensionele immunotoetse wat ge-
soﬁstikeerde toerusting benodig, uiters tydrowend en duur is. Dit verhoog die
behoefte aan 'n sorgtoestel wat diabetes in staat stel om insulienvlakke op 'n
gereelde basis te monitor, en sodoende te help met die nakoming van 'n streng
dieet en ook algemene mediese gesondheidsorg te verbeter. Immunosensors is
kompakte, analitiese toestelle wat 'n spesiﬁeke antigeen (bv. proteïene) kan
opspoor en meet deur biologiese reseptore, soos teenliggaampies, en spesiﬁeke
opneemmeganismes te gebruik om 'n meetbare sein te genereer. Die Organiese
Elektrochemiese Transistor (OECT) is ontwikkel as 'n belowende alternatief
vir die konvensionele immunotoets. Die elektrochemiese sein wat deur OECT-
gebaseerde immunosensors gegenereer word, word gegenereer as gevolg van die
antigeen-teenliggaambinding. OECT-gebaseerde immunosensors bied vinnige
resultate en vertoon hoë sensitiwiteit en selektiwiteit teenoor die antigeen. In
hierdie projek is 'n unieke, koste-eﬀektiewe OECT-gebaseerde immunosensor
ontwikkel wat in staat is om insulien te meet en vinnig te kwantiﬁseer. As
deel van die navorsing is 'n deeglike literatuuroorsig en agtergrondstudie on-
derneem.
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Chapter 1
Introduction
In this thesis the proposal for the design and development of a device for the
project called, "The Development of a Rapid Immunosensor for the Quantiﬁ-
cation of Insulin" is discussed.
1.1 Problem Statement
According to the Global Report on Diabetes set out by the World Health
Organization (WHO), an estimated 422 million adults globally were diagnosed
with diabetes in 2014, compared to the 108 million in 1980 [1]. This increasing
number in diagnosed patients reﬂects an increase in risk factors associated
with diabetes such as obesity and high blood pressure. Adding to the risks,
1.5 million deaths occurred in 2012 due to diabetes. [1]. Another 2.2 million
deaths occurred caused by high blood glucose, which increased the risks of
other diseases, of one which is cardiovascular (heart) disease. From these 3.7
million deaths, 43% were of people under the age of 70 years.
Diabetes is a serious, chronic disease that occurs either when the pancreas
fails to produce enough insulin (type 1 diabetes), or when the body cannot
use the insulin, produced by the pancreas, eﬀectively (type 2 diabetes) [1].
The incidence of type 2 diabetes can lead to complications in many parts of
the body including morbid obesity aﬀecting the psychological health status,
hypertension, stroke disorders and vascular insuﬃciencies to organs such as the
eye, kidneys, lower limbs and brain [1]. Diabetes can also lead to premature
fatal death during pregnancy. Due to pancreatic exhaustion, the patient will
develop type 1 diabetes requiring insulin which will speed up the disease proﬁle
mentioned above.
It is currently extremely diﬃcult to distinguish between type 1 and 2 dia-
betes without the use of expensive and sophisticated facilities and equipment.
It is also expensive to regularly measure insulin levels due to the cost and
availability of the equipment. The current method and duration of the insulin
tests also present great challenges as it is extremely time-consuming to perform
1
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CHAPTER 1. INTRODUCTION 2
these tests.
1.2 Aims and Objectives
Current methods of diagnosing diabetes and measuring insulin is with the
use of immunoassays which are sensitive analytical tests performed by highly
skilled personnel and equipment. Immunoassays also require large sample
sizes of blood, have long analysis durations and are non-portable. A solution
to this that has received much attention during the last couple of years is the
use of point-of-care (POC) devices. POC devices require minimal training
of personnel, have an inherit rapid response rate, is inexpensive and it can
measure multiple biomarkers simultaneously in the case of spreading epidemic.
Point-of-care testing has been integrated into the health care system to
oﬀer the ability for health care testing outside of these laboratories. There is
therefore an opportunity for these point-of-care devices to substitute the so-
phisticated instrumentation due to the improvement in repeatability, increase
in patient compliance, improved eﬃciency, eﬀective portability and improved
patient outcomes.
The aim of this project is to develop a unique low-cost immunosensor that
will be able to detect and measure insulin quantitatively. The advantage of
such a device will be an inexpensive, readily available and user-friendly device
which can be used as a rapid-diagnostic device to provide better treatment
outcomes. The patient will be able to monitor insulin levels more often as
it is important for diabetic patients to lower their insulin levels in order to
eliminate the extreme health complications.
The objectives of this project are as follows:
1. To develop a rapid immunosensor strip that is capable of measuring
recombinant human insulin protein in low concentrations
2. The immunosensor strip should be able to provide results in no more
than 5 minutes
3. The immunosensor strip should be easily manufacturable using low-cost
fabrication solutions and not exceed a unit cost of $0.1 per strip
4. The immunosensor should be simple, highly sensitive and speciﬁc and
reach a limit of detection of 8 µIU/ml (0.3 ng/ml)
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2
Literature Review
This literature review starts with describing Diabetes Mellitus and how it is
diagnosed and controlled. Next, the attention is turned to insulin and how
it is secreted and currently measured. Thereafter a detailed description is
given of antibodies and how they are applied. Finally immunoassays and
immunosensors are discussed and compared with reference to Organic Thin
Film Transistors (OTFTs) and printed immunosensors.
2.1 Diabetes Mellitus
Type 2 Diabetes Mellitus, also referred to as non-insulin-dependent or insulin-
resistant diabetes, is the subject of the research described in this thesis.
2.1.1 Global Burden of Diabetes
Diabetes imposes a large burden on the global health-care economic system
as well as the wider global economy together with the devastating loss of
lives. The costs involved with diabetes include the direct and indirect costs,
premature mortality (measure of unfulﬁlled life expectancy) and negative eﬀect
of diabetes on the nation's gross domestic product (GDP).
The direct costs associated with diabetes encompasses the expenditures for
treating and preventing diabetes e.g. emergency care, medical supplies such as
injection devices, self-monitoring devices and costs related to long-term care.
The International Diabetes Federation (IDF) estimated the total global health-
care direct costs to be more than 827 billion US dollar in 2016, as a result of
an increase in diagnosed patients [1]. While the primary diabetes cost drivers
are hospital inpatient and outpatient care which are expected to continue to
increase, one other contributing factor is the expenditure increase on patented,
branded medicines for the treatment of diabetic patients. The indirect costs
are related with productivity loss.
3
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Besides the burden on the health-care system, diabetes also imposes a
burden on the aﬀected families in terms of higher out-of-pocket health-care
payments and loss of family income due to the nature of the disability and
premature loss of life [1]. There is also a strong relationship between diag-
nosed patients with diabetes and the risk of catastrophic medical expenditure.
Especially in lower-income countries, health-care payments not paid by medi-
cal aid scheme result in increasing medical expenditure.
2.1.2 Causes of Type 2 Diabetes
Type 2 diabetes is caused by impaired glucose tolerance (IGT) which is a
prediabetic state of hyperglycemia, an abnormally high blood glucose (sugar)
levels in the blood [2]. IGT is caused as a result of insulin resistance with
ensuing insulin deﬁciency impacting skeletal muscle, liver and adipose tissue
(fat tissue). Diabetes is also associated with low-grade chronic inﬂammation
that is due to the activation of the innate immune system which is the non-
speciﬁc defense mechanisms of the human body [2]. The interaction of genetic
and metabolic factors determine the risks of type 2 diabetes. Other aspects
that inﬂuence the severity of type 2 diabetes are ethnicity, family history of
diabetes, unhealthy dietary plans, lack of physical activity, smoking and the
two strongest risk factors, overweight and obesity.
Obesity is complicated by metabolic dysregulation including hypertension
and dyslipidemia (collectively known as the metabolic syndrome) and is the
leading precursor to type 2 diabetes [2]. The dyslipidemia involves high lev-
els of circulating fatty acids originating from the patient's diet, and direct
exposure of muscle cells to these fatty acids impairs insulin-mediated glucose
uptake and leads to insulin resistance [2].
A current method to determine obesity is by calculating the Body Mass
Index (BMI). The BMI calculates the relationship between the patient's height
and weight and is an indication whether the patient is obese (overweight) for
his/her respective height [3]. The BMI is used by health professionals to
assess the risk for any chronic disease such as diabetes. The BMI is calculated
by dividing the patient's weight (in kilograms) by his/her height squared (in
meters squared). A BMI lower than 25 kg/m2 indicates a healthy patient, a
BMI between 25 kg/m2 and 30 kg/m2 indicates the patient is overweight and
a BMI greater than 30 kg/m2 indicates serious obesity. Over time diabetes
causes damage to the heart, eyes, kidneys and nerves which increases the risk
of heart disease and stroke [1]. The damage to the heart can impair blood ﬂow
to important body components and together with nerve damage can lead to
limb amputation.
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2.1.3 Diabetes Measurement and Control
Screening and early detection of type 2 diabetes is essential and enables initi-
ation of patient-centered management to improve glycaemic control and min-
imize future complications [4]. The optimal management for such patients in-
cludes lifestyle interventions such as increased physical activity, healthy diets,
weight loss, terminating smoking habits, decrease alcohol intake and glucose-
lowering therapies to reach desired blood sugar targets [4].
Diabetes is either diagnosed by measuring the glucose level in a blood sam-
ple while the patient is in a fasting state (a willing abstinence from food for a
period of time). An alternative method is by measuring glycated haemoglobin
(HbA1c). The diﬀerence between these two methods is that HbA1c reﬂects the
average glucose concentration over a few weeks and not the glucose concentra-
tion at that moment in time. However, HbA1c does not require the patient to
be in a fasting state but is more expensive than blood glucose measurements.
According to private patient prices of PathCare, a network of pathology labo-
ratories that provide testing of patients' blood (or other specimens) for medical
diagnostic purposes, a HbA1c test costs R280 and a glucose measurement costs
R71.
Diabetes is diagnosed according to World Health Organization criteria [5]
and these criteria include when:
 A fasting plasma glucose is equal to or greater than 7 mmol/L (126
mg/dL).
 The 2-h postchallenge plasma glucose is equal to or greater than 11.1
mmol/L (200 mg/dL).
 HbA1c greater than 6.5% using a DCCT aligned assay.
It is important that the accurate and precise measurement of glucose-
concentration is upheld for the management of diabetes. It is assumed that
measurement of glucose in blood is straightforward; however, it is inﬂuenced
by numerous factors such as origin of the sample (arterial, capillary or venous),
sample preparation, analytical method and whether plasma, whole blood or
serum is used [6].
Glucose is normally measured from venous plasma or capillary whole blood
and diagnostic criteria frequently provide equivalence estimates for these two
methods [6]. Venous plasma measurements include inserting a Venﬂon catheter
into an antecubital vein and extracting a small amount of blood. Capillary
whole blood measurements include using a ﬁne lancet to pierce the skin to
extract a drop of blood from the patient's ﬁnger tips that can be used to test
the glucose concentration from commercial blood glucose monitor devices.
The most common technique for diabetes measurement is the capillary
whole blood measurements using the ﬁne lancet and glucose monitor devices.
This method is ideal because there are numerous patients who fear needles
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which makes venous plasma measurements diﬃcult. Another advantage would
mean more regular testing due to the eﬃciency and simplicity of these devices
because they are developed to be used as home tests.
The preferred method of diagnosing diabetes is the fasting insulin test
which involves analyzing a blood sample taken from a patient that has fasted
for at least eight hours. The main disadvantage of the fasting insulin test
is that it can only be performed in health care environments or laboratories
that have access to expensive testing facilities and equipment such as liquid
chromatography-tandem mass spectrometry. Appendix A presents an ultra-
senstive insulin immunoassay test procedure that exhibits the typical proce-
dure for specimen collection and preparation, product information and warn-
ings, required materials and equipment, and ﬁnally the testing procedure. It
is clear from this document that the current method of measuring insulin re-
quires generally inaccessible equipment and materials which makes it almost
impossible to monitor insulin levels at home or without health care facilities.
Another disadvantage is that due to the tests having to be analyzed in
laboratories by lab technologists, the test results take extremely long to reach
the patient which makes it ineﬀective in a situation where the insulin level
results are required immediately. The cost of a fasting insulin test for a private
patient at PathCare is R240 which is more expensive compared to the fasting
glucose test. This increases the need for a point-of-care device that is able to
provide rapid results at a more suitable price.
2.1.4 Managing Diabetes
The ﬁrst and most important step to maintaining a good quality of life with
diabetes is early diagnosis. If a patient lives undiagnosed, it worsens the health
outcomes drastically. It is therefore crucial for all people to have easy access
to basic diagnostics which should be available in any health-care setting. The
only small advantage of type 1 diabetes over type 2 diabetes is that it presents
symptoms that prompt the patient to get help from health-care services. Some
of these type 1 diabetes symptoms include thirst and weight loss. Type 2 di-
abetes, however, does not present these symptoms and the only reason why
patients would get help from health-care services is when some severe compli-
cations already occur such as vision loss or heart attack.
Some factors of type 2 diabetes are unmodiﬁable such as genetics, ethnic-
ity and age, while other factors such as being overweight (obese), having an
unhealthy diet, a lack of physical activity and smoking can however be man-
aged by the patient through a change in behavior and environment. Type 2
diabetes is generally ﬁrst treated by the lifestyle modiﬁcations such to reduce
weight, to improve glycemic control and also to reduce risk factors and health
complications [7]. Weight loss is achieved by decreasing the total intake of en-
ergy and by increasing eﬀective physical exercise which leads to desired energy
expenditure.
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When lifestyle modiﬁcations are not eﬀective, various anti-obesity drugs
can help with diabetes measurement and control. These drugs either stimu-
late insulin secretion or improve patient sensitivity to insulin by altering the
patient's appetite or absorption of calories to ensure the necessary weight loss
[8]. It is however not ideal to manipulate one of the main functions of the hu-
man body, therefore an appropriate solution would be to have the best dietary
recommendations and plans. The focus of dietary plans should be on quality
of fat and carbohydrates rather than quantity alone, together with balancing
energy intake and expenditure.
There is a progressive decline in β-cell function and insulin sensitivity in
type 2 diabetes, which results on deteriorating glycemic control and the con-
stant need to intensify treatment [7]. Dietary adjustments and exercise are
suﬃcient to achieve adequate glycemic control in <10% of type 2 diabetic
patient's therefore an oral anti-diabetic hypoglycemic agent is generally intro-
duced to help with diabetes management [7].
When a patient is diagnosed with diabetes, the patient should have access
to systematic, ongoing and organized care, administered by skilled health-care
providers [1]. These providers must be able to intervene with medication,
health education and follow-up counseling which should improve the outcome
of the diagnosis. The eﬀectiveness of the programme depends on the recom-
mendations and treatment given by die health-care providers. These providers
should be highly skilled but should also convey to the patient's need to un-
derstand the principles and importance of a healthy diet, suﬃcient physical
activity, commitment to medication and the importance of constant assessment
of the presence or progression of any complications.
2.2 Insulin
Insulin is a hormone secreted by the pancreas that allows the body to use
blood glucose (blood sugar) from carbohydrates in the food intake for energy
or to store glucose for when needed in the future [9]. Insulin is the key that
unlocks the glucose channel and enables glucose to enter the cell and to be
used as energy. Therefore insulin prevents the blood glucose (sugar) level from
getting too high or too low.
The pancreas produces more insulin in response to a sugar level spike caused
by eating a high energy meal. After insulin opens the channels of the cells and
allows the glucose to be used as energy, insulin also encourages the storage
of excess glucose as glycogen in the liver, muscle and fat cells [10]. Other
functions of insulin include the ability to enhance growth of muscle, enhance
learning and memory of the brain functions and modify the activity of enzymes
[10].
In the absence of insulin, the body is not able to utilize the glucose as energy
which results in the glucose remaining in the bloodstream and leads to high
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blood sugar, known as hyperglycemia. The opposite of high blood sugar is low
blood sugar which is known as hypoglycemia. Insulin is considered to be the
most powerful hormone in the body and it is therefore critical to understand
the concept and structure of insulin and how it is secreted inside the body.
By diagnosing insulin levels, it is easier to predict the type of diabetes or
insulinoma [11]. Even in healthy conditions, insulin levels in blood serum can
be in the order of picomolar.
2.2.1 History of Insulin
The discovery of insulin is indisputably one of the greatest achievements in
modern medicine. Insulin was discovered at the University of Toronto in 1921
to 1922 after a series of dramatic events in the history of treating diabetes
[12]. It all began in Germany in 1889 when Oskar Minkowski and Joseph von
Mering discovered that removing the pancreas (pancreatectomy) from experi-
mental animals (speciﬁcally a dog) resulted in severe diabetes mellitus which
later resulted in death. This lead to the speculation that the pancreas had
two functions. The one being digestion and the second was to produce a mys-
terious substances responsible for metabolic control. During that time people
hypothesized that an "internal solution" of the pancreas controls carbohydrate
metabolism [12].
Although the development of purifying and modifying insulin took a further
30 years, the discovery of insulin can be attributed to the Canadian surgeon
Frederick Grant Banting, a senior physiology professor at the University of
Toronto, John James Rickard Macleod, a summer student at the University
of Toronto, Charles Best and ﬁnally James Bertram Collip who had a PhD
in biochemistry from the University of Alberta. Refer to the article by Joshi
et. al. for the complete history, biochemistry, physiology and pharmacology
of insulin [12].
2.2.2 Insulin Structure
As mentioned earlier, insulin is an essential protein-based hormone secreted
by the islet β-cells in the pancreas that allows the body to use blood glucose
(sugar) for immediate energy or as storage for future use. Insulin is the key
which unlocks the cell to allow sugar to enter the cell and be used for energy.
The other functions of insulin include monitoring our metabolism and utilizing
the energy from other ingested nutrients. Insulin also stimulates the uptake of
glucose by muscle and adipose tissue (body fat), stimulates protein synthesis
and glycolysis (the process that is critical to aerobic and anaerobic cellular
respiration).
The pancreas is long shaped gland that is situated deep in the abdomen
between the stomach and the spine [13]. Most people are uninformed about
the importance of the pancreas because it is not felt in our daily lives; how-
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ever, the pancreas is a vital part of the digestive system and important for
the control of blood glucose (sugar) levels. The pancreas is divided into two
functional components. The ﬁrst functional component is the "exocrine" cells
that produce enzymes to help with food digestion. The second functional com-
ponent is the "endocrine" pancreas that is composed of small islands of cells,
called the Islets of Langerhans [13]. These endocrine cells do not release their
secretions into the pancreatic ducts such as the "exocrine" cells, alternatively
they release insulin hormones into the blood stream which controls the blood
glucose levels [13].
Insulin has two precursor molecules namely preproinsulin and proinsulin
and is illustrated in Figure 2.1. Preproinsulin is a single amino acid chain pro-
hormone synthesized at the outer (cytosolic) side of the endoplastic reticulum
(ER), where it undergoes translational translocation across the ER membrane
[14]. The ER has many functions such as synthesis and modiﬁcation but the
most important is that it serves as the intracellular transport system of the
cell, primarily transporting proteins. Preproinsulin encodes only 110 amino
acids which makes it a very small protein. A graphical illustration of these
110 amino acids of preproinsulin is given in Figure 2.2. The gene for pre-
proinsulin is located on chromosome 11 and therefore also the gene for insulin
[7].
Preproinsulin Proinsulin Insulin
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Figure 2.1: Process of insulin synthesis [12]
During this translational translocation across the ER membrane, the pre-
cursor preproinsulin loses its encoding signal peptide sequence (24 amino acids)
and folds to form three oxidized disulﬁde bonds (S) to produce human proin-
sulin (hPI) (refer to Figure 2.1 and 2.2). Proinsulin consists of a polypeptide
B chain (30 amino acid), a polypeptide A chain (21 amino acid) and a con-
necting C-peptide (31 amino acid) [12]. The proinsulin is then transported
to the Golgi Apparatus (GA) of the β-cell where it is packaged into imma-
ture secretory vesicles or vacuoles. The connecting C-peptide is then excised
to form fully bioactive two-chain insulin to be stored in mature vesicles for
insulin secretion [14].
Mature insulin has 51 amino acids, 35 fewer amino acids than proinsulin
due to the removal of the C-peptide and the excess 4 amino acids (refer to
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Figure 2.2: Preproinsulin structure [15]
Figure 2.2). The mature insulin also contains the three disulﬁde bonds (S)
between residue A6-A11, A7-B7 and A20-B19 (refer to Figure 2.3). Due to
the small size of the insulin structure, insulin only has a molecular weight of
5808 Daltons [9] and can be seen in Figure 2.3. Daltons, also known as the
uniﬁed atomic mass unit, is the standard unit of measure to quantify mass on
a molecular scale. 1 Dalton is also numerically equivalent to 1 g/mol.
Figure 2.3: Mature insulin structure [12]
A common standard for medication dosage is either milligrams or grams,
due to it being the standard quantity of mass. Insulin, however, is not dosed in
milligrams or grams and therefore to understand the units of insulin, the basic
understanding of an international unit (IU) is required. The international unit
is an unit of measurement that is internationally accepted as the amount of
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substance. One international unit of insulin is deﬁned as biologically equivalent
to 0.0347 mg of insulin (1 IU = 6nmol = 34.7 µg of insulin)[16]. According to
Iwase et al. [17] the normal insulin level in living humans between meals ranges
from 8 - 11 µIU/ml (0.3 - 0.41 ng/ml) and can increase up to 60 µIU/ml (2.25
ng/ml) after meals. A constant average insulin level greater than 11 µIU/ml
indicates the start of Type 2 diabetes and becomes critical to monitor.
2.2.3 Process of Insulin Secretion
The main stimulant of insulin secretion is elevated concentrations of blood
glucose and occurs in a typical biphasic pattern [7]. The drastic 'ﬁrst phase'
only lasts a few minutes and is due to secretion of preformed insulin, followed
by the sustained 'second phase' which reﬂects the signiﬁcant amount of newly
synthesized insulin that is released from the β-cell. Other stimuli that promote
insulin secretion include increased blood concentration of other fuel molecules
(e.g. fatty acids), taste of food and sight. Figure 2.4 illustrates the biphase
glucose-stimulated release of insulin.
Figure 2.4: Biphasic glucose-stimulated release of insulin [7]
Elevated concentrations of glucose in the extracellular ﬂuid is transported
into the β-cell by facilitated diﬀusion with the help of the GLUT-2 trans-
porter [7]. The glucose is then phoshorylated by glucokinase which acts as
a 'glucose sensor' and couples insulin secretion to the prevailing glucose level
[7]. This results in the generation of ATP energy (Adenosine Triphosphate)
which is transferred back to the cytosol and increases ATP/ADP (Adenosine
Diphosphate) ratio. The increased ATP/ADP ratio leads to plasma membrane
depolarization which cause ATP-sensitive potassium (KATP) channels to close
which causes an inﬂux of extracellular calcium through voltage-gated channels.
The increase in cytosolic calcium triggers the above mentioned translocation
and exocytosis of insulin [7]. The process of glucose-stimulated insulin secre-
tion from the β-cell is illustrated in Figure 2.5.
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The activity of glucokinase also determines the amount of insulin secretion
by governing the rate-limiting step for glucose metabolism in the β-cell [7].
Glucose levels below 5 mmol/L do not trigger insulin release whereas glucose
levels at about 8 mmol/L results in half-maximal stimulation [7]. Therefore
when the β-cell is appropriately stimulated, insulin is then secreted into islet
capillary blood and the connecting C-peptide is also secreted into blood but
has no known biological activity.
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Figure 2.5: Process of glucose-stimulated insulin secretion from the β-cell [7]
2.3 Antibodies
Antibodies (Abs) are highly speciﬁc glycoproteins produced by plasma β-cells
of the immune system in response to pathogenic antigens and belong to the
immunoglobulin supergene family. The primary function of an antibody is to
bind to its speciﬁc antigen and label it for destruction by the immune system.
Antibodies are therefore used to control and stop pathogens and to assist in
an immune response. An antibody is also called an immunoglobulin (Ig) and
was ﬁrst referenced in 1890 by Emil von Behring and Shibasabura Kitasato
[18]. The potential for treatment in humans was immediately apparent after a
publication showed the transfer of therapeutic serum from immunized animals
could cure infected animals from a serious bacterial infection named Diphtheria
[18]. After years of development, antibodies inherit three important and unique
characteristics [8] namely:
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 Antibodies can bind to an extremely wide range of chemicals, cells,
biomolecules and viruses due to the nature of proteins and their binding
sites.
 Antibodies have exceptional speciﬁcity to the target substance it binds
to which enables extremely small volumes of analyte to be detected.
 Antibodies have high binding aﬃnity and strength to the target analyte.
The above mentioned characteristics are the reason why antibodies are
considered ideal for therapeutic interventions and medical diagnosis. This
section discusses the basic structure of an antibody, the two types of antibodies
and elaborates on the three unique characteristics.
2.3.1 Antibody Structure
Antibodies are large Y-shaped molecules that consists of two distinct regions
and have a molecular weight of approximately 150kDa [19]. The upper-half
is used as the antigen-binding fragment (Fab) and the lower-half is a crystal-
lizable fragment (Fc). The upper-half consists of two identical "heavy" (H)
polypeptide chains and two identical shorter "light" (L) chains folded into
constant (C) and variable (V) domains and is shown in Figure 2.6. The two
variable domains form the variable fragment (Fv) and provides the antigen
speciﬁcity and the antigen binding site. The two constant domains provides
the structural framework.
Disulfide Bridges
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Fc
Fab
Light Chain
Antigen
Binding
Site
Variable Portion
Constant
PortionC H
C L
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H
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L
V
L
V
H
V L
V H
Figure 2.6: Antibody Structure [20]
Every antibody has a diﬀerent type of heavy chain which categorizes anti-
bodies (immunoglobulin) in ﬁve classes namely IgG, IgA, IgD, IgE and IgM,
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which diﬀer on the basis of size, charge, amino acid composition and carbo-
hydrate content [8]. All ﬁve classes are secreted by the activated β-cells as
glycoproteins [18]. In IgG, IgA, IgD antibody classes, the Fab is separated
from the Fc by a ﬂexible hinge region (not illustrated in Figure 2.6) whereas in
IgE and IgM classes an extra constant domain replaces the hinge which makes
it less ﬂexible [18].
IgG antibodies are the most abundant class of antibody and used almost
exclusively in immunoassays. IgG antibodies are the highest produced anti-
bodies in response to immunization, have the highest binding aﬃnity and are
the most stable during the isolation and puriﬁcation processes.
2.3.2 Types of Antibodies
There are millions of diﬀerent proteins in a single cell, therefore the use of an
antibody is extremely favorable due to its high speciﬁcity to antigens. There
are three diﬀerent types of antibodies namely monoclonal, polyclonal and re-
combinant antibodies. These antibodies have frequently been selected for a
wide variety of applications, including immunodiagnostics and biomarker de-
tection [21].
A monoclonal antibody (mAb) is a single antibody produced by single an-
tibody producing β-cells that only bind to unique sites on the antigen and
causes the antibody to only recognize a particular antigen [22]. The speciﬁc
monoclonal antibody and antigen binding is discussed in Section 2.3.3. Mono-
clonal antibodies are produced using traditional hybridoma-based technologies
which involves the injection of a speciﬁc antigen into a host species (typically a
mouse) in order to provoke an immune response. The β-cell then produce these
monoclonal antibodies that bind to the injected antigen where after it is har-
vested from the mouse's spleen and fused with tumor cells, also called myeloma
cells to produce a hybrid cell line called a hybridoma. The hybridoma has both
the antibody-producing ability of the β-cell and the exaggerated longevity and
reproductivity of myeloma cells.
Polyclonal Antibodies (pAbs) are antibodies secreted from diﬀerent β-cells
that recognize multiple binding cites on the same antigen [22]. The inherent
nature of polyclonal antibodies means that a selection of diﬀerent epitopes may
often be recognised on a single cell; however, as discussed in Section 2.3.3, poly-
clonal antibodies are also produced using traditional hybridoma-based method
when cultured in rabbits, goats or sheep [21]. Polyclonal antibodies are inex-
pensive to produce, but can have a higher chance of cross-reactivity.
Recombinant antibodies (rAbs) are monoclonal antibodies which are not
produced using traditional hybridoma-based technologies, but produced in
vitro using synthetic genes and therefore do not require a host species. This is
a preferred method due to the signiﬁcant pain and discomfort endured by the
animals. Due to the absence of an immunization step, recombinant antibodies
have a faster production rate and are smaller in size, but require experienced
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personnel for the production. For diagnostic manufacturing and therapeutic
drug development that require large volumes of antigen speciﬁcity, monoclonal
antibodies are the ideal solution [22]. However, for general research applica-
tions, the advantages of polyclonal antibodies outweigh those of monoclonal
antibodies [22].
2.3.3 Antibody Speciﬁcity
The antibody-antigen interaction is a non-covalent speciﬁc chemical reaction
between these antibodies and the antigens during an immune reaction. There
are two main components that facilitate these interactions namely epitopes
(antigen) and paratopes (antibody) and Figure 2.7 illustrates these compo-
nents together with their respective carrier.
Polyclonal Antibody
Epitopes
Antigen 1 Antigen 2
EpitopesParatopes
Monoclonal Antibody
Figure 2.7: Antibody-antigen binding diﬀerences between polyclonal and mon-
oclonal antibodies [23]
An epitope refers to the speciﬁc target on the antigen onto which an indi-
vidual antibody bind [22]. This means that the binding between the antibody
and the antigen does not occur between the entire full-length antigen, but
involves only the speciﬁc segment. On any given antigen (protein) there are
multiple unique epitopes onto which speciﬁc antibodies can bind. The bind-
ing between the antibody and the epitope occurs at the antibody binding site,
which is also called a paratope and is located at the tip of the variable fragment
of the antibody [22]. Refer to Figure 2.6 and 2.7 for a graphical representation
of the epitopes and paratopes.
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The critical feature of a paratope is that it can only bind with one unique
epitope which enhances the speciﬁcity of these bindings. The speciﬁcity al-
lows precise detection of a target antigen while avoiding detection of unrelated
antigens that are not of interest [22]. Figure 2.7 illustrates two diﬀerent anti-
gens and a polyclonal and a monoclonal antibody. It can be noted that both
antigens possess three epitopes (only for illustration purposes) where two of
the epitopes are similar on both antigens, and the third epitope diﬀers on
both. The polyclonal antibody possesses two diﬀerent paratopes on the ends
of the variable fragment (Fv) and the monoclonal antibody possesses similar
paratopes at both ends of the variable fragment.
It can therefore be noted that the polyclonal antibody is able to bind to
both antigen 1 and antigen 2 due to the available epitopes on the antigens
and the nature of the paratopes on the antibody. However, the monoclonal
antibody is only able to bind to antigen 2 due to the nature of the paratopes
and the lack of the appropriate epitope on antigen 1. It can therefore be con-
cluded that monoclonal antibodies are more antigen speciﬁc than polyclonal
antibodies.
2.3.4 Antibody Binding Aﬃnity
Antibody binding aﬃnity refers to the strength with which the epitope binds
to an individual paratope on the antibody [22]. Antibodies with high bind-
ing aﬃnity tend to bind quickly to the antigen, permit greater sensitivity and
maintain its bond more readily under diﬃcult conditions. In contrast, anti-
bodies with low binding aﬃnity bind weakly to the antigen and often do not
detect the desired antigen. The binding between an antibody an its antigen
is a reversible process, and the rate of the binding reaction is proportional to
the concentrations of the reactants is expressed in Equation 2.1 below:
[Ab] + [Ag]
 [AbAg] (2.1)
where [Ab] respresents the antibody concentration and [Ag] represents the
antigen concentration, either in bound ([AbAg]) or free ([Ab],[Ag]) state.
Antibody binding aﬃnity is typically measured and indicated by the dis-
sociation constant (KD) which is used to rank and evaluate biomolecular in-
teraction strengths. The KD constant is the ratio of the antibody dissociation
rate (koff ) which is how quickly the antibody dissociates from its antigen, to
the antibody association rate (kon) which is how quickly the antibody binds
to its antigen. The equilibrium dissociation constant is expressed in Equation
2.2 below:
KD =
koff
kon
=
[Ab][Ag]
[AbAg]
(2.2)
The dissociation constant is inversely related to the aﬃnity therefore the
smaller the KD value, the higher the aﬃnity. The dissociation constant is a
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unitless constant which can be correlated with a molar concentration (sensi-
tivity) ratio that ranges from micromolar (10−6) to femtomolar (10−15) values.
Typical antibodies have KD values in the low micromolar to nanomolar (10
−9)
range whereas antibodies with high aﬁnity have KD values in the picomolar
range (10−12).
2.4 Immunoassays
Immunoassays are sensitive analytical tests that measure either the presence
or concentration of an analyte through an antibody-antigen binding. The basic
principle of an immunoassay is to produce a measurable signal in response to
the binding event [24]. The target molecule detected by an immunoassay is
called the analyte and is isolated using the appropriate antibody.
Immunoassays were ﬁrst expounded in 1959 by Rosalyn Yalow and Solomon
Berson, and since then there has been a continuous growth, not only in the
range of applications, but also in the number of assay designs [8]. The con-
tinuous improvements led to more sensitive assays that have opened up new
horizons of clinical research and diagnosis. Immunoassays are currently still
used for medical and research purposes and remains an invaluable tool for
pharmaceutical analysis such as clinical diagnosis of diseases, drug discovery
and development, and therapeutic drug monitoring.
The advantage of immunoassays is that it enables the above-mentioned in-
dustries to measure low concentrations of low molecular weight drugs, macro-
molecular biomolecules, metabolites and biomarkers which indicate and aid
disease diagnosis or prognosis [25]. The signiﬁcance of immunoassays are at-
tributed due to their speciﬁcity, high-throughput and sensitivity.
2.4.1 The Basic Working Principle of Immunoassays
The reagents required for immunoassays are antibodies, signal-generating la-
bels and separation matrices. The most important component of an immunoas-
say is, however, the antibody, and the reaction between the antibody and the
analyte is the driving force of immunoassays. This reaction can vary consider-
ably and is of profound signiﬁcance to an eﬀective assay [8]. These reactions
can take from a few seconds to few hours, depending of the nature of the re-
action and various factors. During the initial development of immunoassays,
overnight incubations were necessary to allow the reaction to reach full equi-
librium. Since then, immunoassays have developed signiﬁcantly to allow for
shorter incubations and more eﬃcient assays.
Important factors to take into consideration when choosing the appropriate
antibodies include the type of antibody (monoclonal, polyclonal or recombi-
nant), puriﬁed or native, whether to purchase or manufacture antibodies and
whether the antibodies should be fragmented, bispeciﬁc or fusion proteins and
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most importantly the cost. During immunoassay development for pharmaceu-
tical analysis purposes, monoclonal antibodies are preferred due to their high
binding aﬃnity and speciﬁcity towards the analyte [25].
Immunoassays can be performed in two diﬀerent formats namely compet-
itive or non-competitive, and the choice of immunoassay format is based on
the nature of the analyte, labeling availability and the required analytical pa-
rameters such as sensitivity, speciﬁcity, accuracy and dynamic range [25]. In
competitive immunoassays, the sample analyte is mixed together with a la-
belled analyte, which both compete for a limited number of antibody-binding
sites [20]. Figure 2.8 graphically shows the diﬀerent immunoassay formats.
In the antigen-capture format (Figure 2.8a), the competitive reaction occurs
between the labelled and unlabeled analyte.
In non-competitive immunoassays, the target analyte is captured by an
excess of capture antibodies which is then separated from the analytes left in
the solution [20]. The captured analyte is then exposed to an excess of detec-
tion antibodies which will only bind to available epitopes. Non-competitive
immunoassays are also referred to as "two-site" or "sandwich" immunoassays
and is shown schematically in Figure 2.8b. The one antibody is immobilized
onto a solid support (e.g. a well in a microtiter plate) to capture the target
analyte and is called the primary or capture antibody. The second antibody
is used as the basis of the signal generation component and is labeled with a
tag which facilitates the detection and puriﬁcation. This antibody is referred
to as the secondary or detection antibody.
solid phase 
substrate
analyte
labeled
analyte
capture antibody
labeled
detection
antibody
a) b)
Figure 2.8: Schematic diagram of the a) competitive and b) non-competitive
immunoassay conﬁguration [20]
2.4.2 Immunoassay Detection Techniques
The main objective of an immunoassay is to produce a measurable signal in
response to the antibody-antigen interaction. The signal is produced by a
detectable label that is employed by the assays and is also the second most
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important reagent on which the success of any immunoassay depends. The
desired label is generally chemically linked or conjugated to the secondary an-
tibody or antigen (depending on the type of immunassay format). A standard
curve representing the measured signal as a function of the concentration of
the analyte in the sample is constructed and can be used to determine the
concentration of the unknown analyte [25].
As the ﬁeld of biotechnology and immunoassays advances, new techniques
are constantly developed, but for the purpose of this study only four techniques
are discussed. These methods and techniques are Radioimmunoassay (RIA),
Enzyme-linked Immunosorbent assay (ELISA), Electrochemiluminescent Im-
munoassay (ECLIA) and Chemiluminescent Immunoassay (CLIA). Other tech-
niques include Counting Immunoassay (CIA), Fluorescent Immunoassay (FIA),
Liposome Immunoassy (LIA), and Magnetic Immunoassay (MIA), but are not
discussed in this thesis.
2.4.2.1 Radioimmunoassay
The radioimmunoassay (RIA) is the oldest type of immunoassay and is also the
ﬁrst technique used to measure and quantify insulin in the late 1950s by Berson
and Yalow [26]. In RIAs, a radioisotope is conjugated to a known concentration
of a desired antigen and bound with its complementary antibody. When the
sample solution is added, the target antigen competes with the radioactive
antigen and replaces it on the binding spot. The unbound antigens are then
washed away and the radioactivity of the sample is measured. The radioactive
signal is therefore inversely related to the amount of target antigen that is
bound to the antibodies.
The advantages of RIAs include the accuracy, low detection limit and ex-
treme sensitivity which can not be achieved by the other techniques [25]. The
disadvantage of the technique is the health hazard of radioactive substances
and the requirement for a license to handle radioactive material. RIAs also
require highly trained personnel and storage facilities.
2.4.2.2 Enzyme-linked Immunosorbent Assay
Enzyme-linked Immunosorbent Assays (ELISAs) are analogous to RIAs; how-
ever, the main diﬀerence is the enzymatic label instead of the radioisotope
[25]. In ELISA tests, the enzyme molecule is coupled onto the antigen (Ag),
or antibody, and catalyses the chemical reaction. After the separation of un-
bound factions and adding an additional desired substrate, the assay possesses
measurable physical and chemical diﬀerences. One approach is to have a col-
orless chromogenic substrate which is converted to a colored product due to
the reaction of the enzyme [25]. The color change can be measured with a
spectrophotometer and the signal is directly correlated to the analyte concen-
tration.
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Commonly used enzymes are Horseradish Peroxidase (HRP) and Alkiline
Phosphatase (ALP). Although ELISA tests have evolved signiﬁcantly to the
point where it is the most common assay test today, the main disadvantage is
that it is only possible to measure a single analyte at a time due to the nature
of the ELISA plates. There are four common ELISA conﬁgurations based on
their structure namely direct ELISA, indirect ELISA, competitive ELISA and
non-competitive ELISA (sandwich ELISA), illustrated in Figure 2.9 below.
Direct ELISA
Substrate
Primary Antibody
Conjugate
Ag
Secondary Antibody
Conjugate
Capture Antibody
Inhibitor
Antigen
Indirect ELISA Sandwich ELISA Competitive ELISA
Substrate
Substrate
Substrate
Figure 2.9: Comparison between ELISA conﬁgurations [8]
The objective of a direct ELISA test is to detect and measure antibodies
instead of antigen. In direct-ELISA tests, a known concentration of antigen
is ﬁxed to the surface of the microtitre plate rendering it immobile. The
advantages include the use of a single antibody which makes it inexpensive
and quicker to gather results. The cross-reactivity of the secondary antibody
is also eliminated. The disadvantages include the limited signal ampliﬁcation,
the time consumed by labeling primary antibodies for each ELISA-test and
the cost.
In indirect-ELISA tests, the objective is also to detect antibodies therefore
a known concentration of antigen is coated onto the microtitre plate. The
advantages of indirect-ELISA tests include high sensitivity due to the use of a
labeled secondary antibody which can bind to various epitopes on the target
antibody allowing for signal ampliﬁcation and the high ﬂexibility due to wide
variety of secondary antibodies available. Another advantage is the possibility
to use various diﬀerent visualization labels. The main disadvantages include
the possibility of cross-reactivity due to the secondary antibody and that the
use of a secondary antibody adds additional incubation steps making it more
time consuming and more expensive.
Competitive ELISA tests make use of a competitive binding process exe-
cuted by the original antigen and add-in antigen. Competitive ELISA tests
are very speciﬁc due to the use of two antibodies. It can also be used in com-
plex samples since the antigen does not require any puriﬁcation before any
measurements. One major disadvantage of competitive ELISA tests is due to
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the inverse rule, past a certain limit of detection, the signal strength becomes
unreadable.
The most common type of ELISA test is the sandwich ELISA test that
measures the presence or concentration of an antigen between two layers of
antibodies (i.e. capture and detection antibodies). The sandwich ELISA tech-
nique is an extremely sensitive and accurate assay due to the use of two an-
tibodies. The only challenge is to ﬁnd the correct antibody pairs that do not
interfere and match due to their clonality. When monoclonal antibodies are
used, it is critical to have diﬀerent epitopes they bind to. Other advantages
of ELISA tests include the versatility of possible analytes, high speciﬁcity and
sensitivity, no radiation hazards, ease of process, widely available equipment
and the fact that ELISAs produce qualitative and qualitative results. Another
potential advantage of ELISAs is the possibility of amplifying the signal in
order to get the desired sensitivity for the analysis [25]. The limitations of
ELISA tests include possible false positives or false negatives and when using
the sandwich conﬁguration, can be expensive and time-consuming.
2.4.2.3 Chemiluminescent Immunoassay (CLIA)
Chemiluminescent Immunoassays are also analogous to ELISAs and RIAs,
but it uses a chemiluminescent substance as a label for signal generation [25].
Luminescence is the emission of light to due an electron being in a higher
energy level and emitting a photon as it comes down to normal energy level.
CLIAs are similar to Flourescent Immunoassys (FIA), but FIAs utilizes the
eﬀect with certain frequencies of light whereas CLIAs uses a chemical reaction.
CLIA signals are measured using photodetectors that detect or respond to
incident light using the individual photon electrical eﬀect [27]. CLIAs are
ultra-sensitive, can detect small amounts of the biological molecule and has a
wide dynamic range.
2.4.2.4 Electrochemiluminescent Immunoassay (ECLIA)
Electrochemiluminescenct Immunoassays (ECLIA) are also based on lumines-
cence however, the signal is generated by a speciﬁc electrochemical reaction.
When electrochemically generated intermediates are stimulated by electricity,
they undergo reactions that release energy which also emits lights upon relax-
ation back to a lower energy level. ECLIA signals can therefore be measured
without a photodetector which makes it an extremely attractive technique due
to the inherit luminescence and electrochemical properties [27].
The advantages of ECLIAs include high sensitivity, possibility to amplify
signals and enhance light levels and a broad dynamic range. ECLIAs are also
relatively easy to use, has great ﬂexibility when the labels are stable, non-
radioactive, and conveniently conjugated to the target biological molecules,
and lastly, ECLIAs has unsurpassed performance and quality that inherits
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a highly successful detection system that achieves clinical quality data in a
variety of sample types.
2.4.3 Blood, Pooled Plasma and Serum
The most common specimen samples used in immunoassays are blood, plasma,
serum, urine, milk and saliva, each with various desirable analytes. Blood
consists of four components namely red blood cells which carry oxygen through
the body, white blood cells which are the cells of the immune system to protect
the body against infectious diseases and foreign substances, platelets which
prevent excessive bleeding and plasma, a yellowish liquid that carry nutrients,
hormones and proteins through the body. Blood is the most desirable sample
for clinical diagnosis and prognosis of serious infectious diseases as the plasma
possess millions of biomarkers and proteins [28].
Biomarkers are naturally occurring molecules or genes by which diseases
(such as diabetes) or physiological process can be identiﬁed. The quality of the
biomarkers present in blood depends on biological factors such as the physical
condition and age of the patient, but also depends on technical factors such as
sample collection and preparation [28]. Although blood is the most common
sample collected from patients, the plasma has to be separated from the other
components and prepared for immunoassay testing. In bad separation proce-
dures, blood cells can cause contamination and degrade the sample. Currently
blood plasma separation (BPS) relies on a bench-top centrifuge to produce
plasma. It is therefore critical to improve microscale blood plasma separation
to achieve a reliable point-of-care device.
Plasma is the yellowish liquid portion remaining after centrifuging blood
with anti-coagulants (also referred to as blood thinners) that prevent or re-
duce the coagulation (clotting) of blood. Serum is however the undiluted,
extracellular portion of blood remaining after coagulation (clotting). Serum is
therefore the plasma excluding the clotting substances.
Current point-of-care devices avoid BPS due to the inconsistencies intro-
duced during the separation, resulting in lower concentration of target ana-
lytes, inaccurate measurement and reduced assay sensitivity [28]. There is
however a trade-oﬀ between using blood in point-of-care devices that has in-
accuracies due to blood cells, or using integrated BPS membranes that has
inaccuracies due to the separation eﬀectiveness. The quality of the analytical
methods does however not always guarantee the diagnostic success. Accord-
ing to Mielczarek et al. [28], an important but overlooked issue relates to the
variability in sample collection, storage and processing, accounting for up to
70% of all laboratory errors.
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2.4.4 Immunoassay Performance Parameters
As the main objective of immunoassays is to provide prompt, accurate and
reliable data, the validation method should be an inherent part of the de-
velopment process. A number of validation and performance characteristics
have been deﬁned to emphasize the importance of the quality of the analytical
process [29]. Some of these parameters include reusability, clinical stability,
reproduceability, selectivity, robustness and measuring range. The success of
immunoassays is generally attributed to the four main parameters sensitivity,
speciﬁcity, accuracy and precision [8].
Sensitivity
Sensitivity refers to the quantitative measurement of the concentrations of the
desired analyte. Analytical sensitivity refers to the ability of a test to detect
a target analyte expressed as the minimum detectable concentration of that
desired analyte. The approach is to assay the zero concentration calibrator
repeatedly to deﬁne the limit of sensitivity (through a calibration curve) as
the concentration that falls 2 or 3 standard deviations above the mean [8]. The
values at this limit are not necessarily reliable as one assumes that the ﬁtted
calibration curve is an accurate reﬂection of the true dose-response, which in
real clinical situations might diﬀer.
Speciﬁcity
Assay speciﬁcity refers to the ability of an antibody to produce a measurable
signal in response to only the desired analyte [8]. Cross-reactivity is a mea-
surement of the response of an antibody to substances other than the target
analyte. Many proteins are closely related owing to their structures and can
lead to cross-reactivity. The level of cross-reactivity can be monitored by ei-
ther using the right antibodies in a competitive assay design or by using a
sandwich design with the highly speciﬁc antibodies.
Accuracy
Accuracy refers to how close the average measured signal is to the true value
through the use of reference standards and calibration curves from laboratories
and previously established reference data. This can be a diﬃcult task as for
many analytes, no true reference methods or data exists to compare measured
data against. It is therefore critical to make sure that all possible causes of
variations are eliminated from assay designs. This is also a key characteristic
of POC devices where multiple electronic devices can cause interference and
noise in the measured signal. It is important that a well deﬁned concentration
standard and reference material is available during assay tests.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2. LITERATURE REVIEW 24
Precision
Precision refers to the repeatability and minimal (standard) variation between
measurements of an analytical technique [8]. Imprecision is the opposite of
precision and refers to an estimate of errors in the analytical technique, there-
fore high precision also refers to low imprecision. Assay precision is aﬀected by
multiple contributors due to variation, separation and detection errors. Other
contributors include ill-deﬁned antibody concentrations, poor antibody immo-
bilization techniques, temperature ﬂuctuations or spikes, ionic strength and
instrumentation variations and ineﬃciencies.
2.4.5 Immunoassay Considerations
Immunoassay techniques have been the ﬂagships for drug monitoring and an-
alyte quantiﬁcation, however since the development of POC devices, the dis-
advantages of immunoassays relative to POCs became apparent. The major
drawback of immunoassays is the fact that it requires expensive equipment
and trained staﬀ and that it is extremely expensive and time consuming. The
need for these rapid analytical POC devices is increasing as millions of people
in third world countries are deprived of proper medical resources and care.
2.5 Immunosensors
Immunosensors are compact analytical devices that detect speciﬁc analytes
by using biological receptors such as antibodies, enzymes, cellular receptors,
nucleic acids, microorganisms or artiﬁcial biomemetric materials [30]. More
speciﬁcally, immunosensors are aimed to detect the presence of speciﬁc antigens
and antibodies that are important for the diagnosis of diseases.
The advantage of immunosensors is that the clinical testing process is ex-
tremely fast compared to that of the generally used immunoassays. In im-
munoassay testing, many parties are involved and this inﬂuences the eﬃciency
of processes such as testing of the patient, transport of samples, analysis, vali-
dation of results, reporting of results. Only then the patient can be contacted.
Point-of-care devices, such as immunosensors, implement four basic steps dur-
ing the procedure. These steps are: making the decision to test, sampling from
the patient, performing the test and immediately obtaining results to inform
the patient. This is however only one of the reasons to improve POC devices.
The other reasons are that it requires minimal training or personnel, it is fast,
cost-eﬀective and able to diagnose multiple antigens simultaneously in the case
of a rapidly spreading epidemic [31].
Immunosensors consists of three main components that work together in
an integrated fashion to deliver successful results. These components are: a
sensitive biological element, a transducer and a signal processor. An optional,
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but not essential, component can be a display unit. Figure 2.10 shows the
components of an immunosensor.
Sensitive
Biological
Element
Transducer SignalProcessor
Display
Results
Figure 2.10: Components of an immunosensor [32]
The sensitive biological element functions as the recognition system and
detects the analyte via the formation of antigen-antibody complexes in body
ﬂuids, especially in serum. This antigen-antibody complex generates chemi-
cal signals due to physical and chemical changes which are converted into an
electrical signal by means of the transducer [31]. The ﬁnal component is sig-
nal processing where the electrical signal is received, analysed, processed and
returned to an optional display.
Various transducing mechanisms are used in immunosensors, based on the
signal generation or property changes following the antigen-antibody reaction.
Signal transducing can be carried out by various means, but this research fo-
cuses on immunosensors that measure electrons, photons and mass changes.
Other types of transducing mechanisms include thermal changes and pH vari-
ations but are omitted from this thesis.
Optical Immunosensors
In optical immunosensors, the biological recognition element responds to the
interaction with the target analyte (antibody) and generates an optical sig-
nal, such as ﬂuorescence, or undergoes changes in optical properties, such as
absorption, reﬂectance, emission, refractive index, and optical path [31]. The
optical signal is then collected by a photodetector which converts the perceived
light signals to electrical signals that can be digitally processed.
Piezoelectric Immunosensors
Piezoelectric immunosensors measure the change in mass due to antigen-antibody
complex formations, compared to the mass of the antigen and antibodies sep-
arately. Two of the most popular piezoelectric immunosensors are quartz crys-
tal microbalances and microcantilevers, which vibrate at a certain frequency.
Piezoelectric immunosensors detect a vibration frequency shift as a result of
the formation of antigen-antibody complexes.
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Electrochemical Immunosensors
Electrochemical immunosensors react to the formation of antigen-antibody
complexes and generate an electrical signal which can then be digitally in-
terpreted and processed for analysis. The three main electrochemical trans-
ducers are: amperometric, potentiometric and conductimetric (impedimetric)
[31]. Amperometric immunosensors measure current or the change in current,
whereas potentiometric or voltammetric immunosensors measure electrode po-
tential or voltage diﬀerences while impedimetric immunosensors measure the
conductivity or resistance. Electrochemical immunosensors are fast, sensitive
and inexpensive and are commonly used in point-of-care devices.
2.6 Organic Thin Film Transistors
Organic Thin Film Transistors (OTFTs) have been a popular research topic in
the scientiﬁc community in recent decades and have received a fair amount of
attention due its ability to be used as immunosensors in POC devices. OTFTs
are highly sensitive, highly selective, have inherent low detection limits, low
production and fabrication costs, and are extremely ﬂexible [33]. OTFTs have
the desirable ability to be miniaturized and integrated into portable electronic
devices due to the nature of their design. In addition, the use of organic
materials is considered to be compatible with the highly sensitive biological
elements. This also allows tailoring of the organic material and the adjust-
ment of its chemical and physical properties to ﬁt the need of the application.
Transistor-based sensors obtain their high sensitivity due to inherent com-
bination of a sensor and an ampliﬁer into the design, therefore, OTFTs show
promising applications in chemical and biological sensors. OTFTs are also used
in a variety of applications such as light sensing, environmental monitoring,
drug delivery, food safety and medical diagnostics [34].
OTFTs are three-terminal electrical devices (similar to the popular conven-
tional MOSFET, Metal-Oxide-Semiconductor Field-Eﬀect Transistor) that en-
ables for the control of a current that ﬂows between two electrodes (the source
and drain), through the modulation of an applied voltage at the third elec-
trode (the gate) [33]. The measured current is referred to as the drain current
(ID) and can either ﬂow from drain to source or vice versa, depending on the
transistor setup and applied voltages. The critical active channel between the
source and drain electrodes, consists of a thin ﬁlm of an organic semiconduc-
tor which establishes electrical contact between the source and drain electrodes
while they do not have physical contact. OTFTs have been used in a variety of
gas sensors, cell sensors, chemical sensors (such as humidity, ions and pH) and
biological sensors (such is DNA, enzyme, antibodies, tissues, micro-organisms,
glucose and dopamine) [34]. Highly sensitive biological and chemical sensors
are in great demand especially for environmental monitoring, food safety tests,
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medical analysis and health-care products.
The organic semiconductor acts as the channel for current to ﬂow and the
magnitude thereof is modulated by the gate voltage [35]. This enables the
sensors to detect the target analyte due to the physical or chemical changes in
the semiconductor [35]. Therefore OTFTs are used in immunosensors as the
transducing mechanism (or sensing platform). OTFTs use an electrochemi-
cal approach where the biological elements are immobilized onto the sensor
in order to give an electrical signal due to the chemical change in the semi-
conductor. However, an OTFT can also be used as an optical immunosensor
where a colorimetric probe can be conjugated to the biological element which
generates an optical signal.
2.6.1 Organic Thin Film Transistor Architectures
The name OTFT is generally used to describe most types of organic transistors,
but they can also be classiﬁed into two types of transistors according to the
operation principles and device structures, namely, Organic Electrochemical
Transistors (OECTs) and Organic Field-Eﬀect Transistors (OFETs) [34].
Recently, Electrolyte-Gated Organic Field-Eﬀect Transistors (EGOFETs),
a new type of transistor architecture, has attracted much attention due to the
low operating voltages compared with OFETs gated with solid dielectrics [36].
EGOFETs are similar to OECTs in that the gate is separated from the semi-
conductor by an electrolyte, but it is similar to OFETs in that it does not rely
on ion transfer to modulate the current. An Ion Sensitive Organic Field-Eﬀect
Transistor (ISOFETs) is another sub-architecture of OTFTs where the basic
structure is similar to EGOFETs, with only the addition of an insulator (dielec-
tric layer) that separates the electrolyte and the semiconductor. EGOFETs,
ISOFETs and OFETs use an organic semiconductor where electrons (or holes)
are the main charge carriers. OECTs use an organic electrically conductive
polymer (ECP) which has ions and electrons (or holes) as the charge carri-
ers. The architecture, structure and respective channels (indicated in red) of
OECTs, OFETs, EGOFETs and ISOFETs are illustrated in Figure 2.11.
Organic Electrochemical Transistors
The ﬁrst Organic Electrochemical Transistor (OECT) was developed in the
early 80's when White et al. [37] used an organic material as the active com-
ponent of a transistor [36]. Since then, OECTs have been extensively investi-
gated as a promising platform for a variety of chemical and biological sensing
applications such as ions, pH, glucose, dopamine, bacteria, cells, and tissues,
etc. [38].
OECTs are three-terminal devices in which the source and drain is con-
nected via an electrically conducting polymer (ECP). OECTs can either op-
erate in accumulation mode or depletion mode. The operating principle of an
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Figure 2.11: Comparison between diﬀerent Organic Thin Film Transistor con-
ﬁgurations [36]
OECT relies on the doping or de-doping of the conductive polymer (semicon-
ductor) which changes its conductivity due to the migration of mobile ions
into or out of the semiconductor from the electrolyte [36]. In accumulation
mode, applying a gate voltage, switches on the OECT by injecting ions into
the semiconductor, thus increasing the carrier concentration. In depletion
mode, applying a gate voltage switches oﬀ the OECT by injecting ions into
the semiconductor which compensates for native dopants and reduces the car-
rier concentration.
One advantage of using an organic ECP is the fact that the doping/de-
doping processes are reversable and therefore can be switched by the applied
gate voltage [35]. Another advantage is the ease of fabrication since the gate
electrode and the channel are separated. It is consequently more convenient
to fabricate an array of OECTs or to integrate them into microﬂuidic channels
[34]. The most common organic ECP used is poly(3,4-ethylenedioxythiophene)
polystyrene sulfonate (PEDOT:PSS) [36], however PEDOT:PSS and various
other polymers are discussed in detail in Section 2.6.2. PEDOT:PSS is a
depletion mode p-type semiconductor which uses holes as the charge carriers.
OECTs that use PEDOT:PSS are normally-on devices which causes current
to ﬂow without the application of any gate voltage, due to the holes being
the charge carrier. Therefore PEDOT:PSS based OECTs are depletion mode
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transistors. One major disadvantage of OECTs are their low switching speed
due to the intrinsically low mobility of the ions in the electrolyte and the
restricted speed of the redox reaction [39].
OECTs are generally characterized using an electrolyte called Phosphate
Buﬀered Saline (PBS). PBS is a balanced water-based salt solution commonly
used in biological research. PBS inherits the desirable ability to maintain a
constant pH (generally pH 7.4) and also has osmolarity and ion concentrations
matching those of the human body. PBS is formulated by two salts named
calcium chloride (CaCl2) and magnesium chloride (MgCl2) which facilitate
the ion transfer in OECTs.
Upon the application of a positive gate voltage, the magnesium and cal-
cium cations (positively charged ions) are extracted from the electrolyte and
penetrate the conductive polymer and accumulate inside the ECP and replaces
the native holes inside the ECP. The positively charged gate electrode then
attracts the negatively charged chlorine (Cl2−) anions as shown in Figure 2.12.
This causes a decrease in hole density which reduces the conductivity of the
polymer because fewer holes exist to carry charge. This is known as de-doping
of the polymer and causes the current to decrease. Applying a negative gate
voltage will dope the polymer, causing the cations to be removed from the
ECP thus causing an increase in hole carriers and the drain current. The ion
transfer as a result of a biased gate voltage is illustrated in Figure 2.12 below.
Gate
Electrolyte
Source Drain
Substrate
Anion (Cl2-)
Cation (Mg/Ca)
Hole
a) Gate
Electrolyte
Source Drain
Substrate
b)
CurrentCurrent
Figure 2.12: Graphic illustration of the OECT ion transfer upon an applied
gate voltage
Due to the doping and de-doping caused by ion transfer, an OECT converts
ionic current into an electronic current and is therefore ideal for monitoring
biological phenomena. Another advantage of OECTs is that they operate at
extremely low voltages (less than 1 V) which is ideal for biosensing in aque-
ous media, where low voltages are required to avoid undesired redox reactions
and to prevent the risk for hydrolysis during operation [36]. In short, ap-
plying a voltage to the OECT gate electrode makes it possible to modulate
the conductivity of the active conductive polymer material "channel" between
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the transistor's source and drain electrodes by electrochemically doping or
de-doping the semiconductor [40].
The schematic in Figure 2.13 shows that the ionic gate current (IG) con-
tributes to the channel current (ICH) by the interaction between electronic and
ionic charge carriers in the channel. Also shown are the drain current (ID) the
source current (IS) the drain voltage (VD) and the gate voltage (VG). The
variable name for the gate current is a lower-case letter to emphasize that it
is a transient current.
VD
VG
Drain
Electronic Current
Ionic Current
Electronic/Ionic Coupling Gate
SourceICH
ID IS
Channel
iG
Figure 2.13: Schematic illustration of the electronic and ionic current in
OECTs [40]
The eﬀective gate voltage (V effg ) represents the potential drop at the channel-
electrolyte and gate-electrolyte interfaces [41]. Upon the immobilization of
antibodies or proteins on the OECT channel, it forms a negatively charged
layer which attracts positively charged ions in the electrolyte. This leads to
a decrease in V effg which means fewer ions are dedoping the semi-conductive
channel which decreases the drain current and threshold voltage [42]. When
no proteins are immobilized, V effg equals VG and therefore the channel current
is only aﬀected by the ionic transfer into the semiconductor. The eﬀective gate
voltage can be described by Equation 2.3 as follows:
V effg = Vg + 2.30(1 + γ)
kT
ne
log[CInsulin] + A (2.3)
where Vg is the applied gate voltage; γ the capacitance ratio (deﬁned as γ =
Cc/Cg, where Cc and Cg are the channel and gate capacitance, respectively);
k the Boltzmann's constant; T the temperature, e the elementary charge; n
(=2) the number of electrons transferred during the electro-oxidation of insulin;
and A is a constant related to other factors. The V effg can be modulated by
changes in sheet resistance, electrolyte resistance, charge transfer and sensing
of external signals such as protein immobilization.
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Organic Field-Eﬀect Transistors
Organic Field-Eﬀect Transistors (OFETs) are somewhat similar to OECTs in
basic architecture, however they diﬀer in that the gate is further separated from
the organic semiconductor by an insulator that acts as a dielectric (refer to
Figure 2.11). Diﬀerent dielectrics can be used for the insulator e.g. polymers,
oxides, vacuum, etc. OFETs also do not require an electrolyte, instead it uses
the insulator to provide the ﬁeld eﬀect doping.
When the gate electrode is negatively biased in a p-channel device, free
holes in the organic semiconductor are drawn closer to the semiconductor-
insulator boundary to compensate for an equivalent negative charge at the
gate-insulator boundary [36]. This build-up of charge leads to the formation
of a conducting channel at the semiconductor-insulator boundary. Thereafter,
when a negative voltage is applied between the source and drain, holes are
injected from the source and current ﬂows inside the channel.
The threshold voltage (the gate voltage required to switch the transis-
tor from its "oﬀ" to its "on" state) of an OFET is greatly aﬀected by the
semiconductor-insulator boundary properties, along with the charge carrier
mobility and the charge current modulation ratio [36]. When a suﬃcient gate
voltage (above the threshold voltage) is applied, a conductive transistor chan-
nel is established for the ﬂow of current.
Electrolyte-Gated Organic Field-Eﬀect Transistors
Electrolyte-Gated Organic Field-Eﬀect Transistors (EGOFETs) have recently
gained much attention due to the minimalist architecture and required compo-
nents. As mentioned earlier, the distinguishing characteristic of an EGOFET
is that the gate is separated from the semiconductor by an electrolyte. Inter-
estingly, it does not require an insulator (dielectric) layer. EGOFETs typically
have a top gate, bottom contact conﬁguration [43]. EGOFETs are similar to
OECTs, the main diﬀerence lying in the interface between the channel and the
electrolyte. In EGOFETs, the ions of the electrolyte create an electrical double
layer (EDL) with the charges of the channel. This implies ions do not pene-
trate into the semiconductor, but rather builds up at the surfaces (interfaces)
[42].
EGOFETs appear to be particularly suitable for use as the sensing platform
for immunosensors due to their simple architecture combined with the low
operating voltage. This can lead to inexpensive sensors having a low power
consumption. EGOFETs also tend to have faster response times than OECTs
due to fast switching times and the fact that the process does not depend on
ion transfer.
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Ion Sensitive Organic Field-Eﬀect Transistors
Ion Sensitive Organic Field-Eﬀect Transistors (ISOFETs) are similar to EGOFETs,
with one distinguishing component which is the insulating layer between the
electrolyte and organic semiconductor. The drain current (ID) is driven by the
potential of the electrolyte-insulator boundary and the channel. In the case of
an immunosonsor, the sensitive biological elements are immobilized onto the
insulator which modulates the drain current.
2.6.2 Organic Semiconductors and Conductive
Polymers
The organic semiconductors (OSC) and electrically conductive polymers (ECP)
are essential to OTFT-based immunosensors as it provides the charge transport
to conduct the eﬀective output current [34]. Conductive polymers and organic
semiconductors also improve stability and sensitivity in OTFTs [42]. Several
active organic semiconductors have been used in OTFT-based sensors such
as polyaniline (PANI), polythiophenes (PTs), polypyrrole (PPy), Pentacene,
poly(triaryl amine)(PTAA), DDFTTF, poly(3-hexylthiophene)(P3HT), poly
(3,4-ethylenedioxythiophene):poly(styrene sulfonic acid)(PEDOT:PSS), etc.
The ability to provide eﬀective charge-transport properties is aﬀected by
various intrinsic and extrinsic factors such as interaction, material purity, ori-
entation, etc. [44]. It is important to note that high purity is desirable as
impurities result in defects and degrade the transport proﬁle which aﬀects per-
formance, causes inferior mobility and instability [44]. Another performance
factor is OSC and ECP ﬁlm thickness. For very thin layers (tSC < 5 nm) stable
continuous ﬁlms are diﬃcult to maintain and charge transport is hampered.
Very thick layers (tSC > 100 nm) may suﬀer from extreme surface roughness,
poor ﬁnish and may have a high sheet resistance due to the long distance for
vertical charge transport [44].
PEDOT:PSS is an electrically conductive polymer (ECP) and is consid-
ered the golden standard and is frequently used in OECTs [36]. PEDOT:PSS
consists of poly(3,4-ethylenedioxythiophene)(PEDOT) combined with a high-
molecular-weight counter-ion named poly(styrene sulfonate)(PSS), having the
molecular structure illustrated in Figure 2.14. The combination of PEDOT
and PSS forms a stable polyelectrolyte complex suspension which can easily
be printed and coated onto ﬂexible substrates. OECTs rely on the character-
istics of PEDOT:PSS as ions are injected into the PEDOT:PSS to change its
doping state and hence alter its conductivity.
A unique characteristic of PEDOT:PSS is that it inﬂuences the OECT to
become a 'normally-on' device which means that without the presence of a
gate voltage, PEDOT:PSS is in a conducting state and can induce a drain
current [36]. Upon application of a positive gate bias, cations (positiviely
charged ions) in the electrolyte penetrate the organic semiconductive polymer
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PEDOT
PSS
Figure 2.14: Molecular structure of PEDOT:PSS [45]
and takes the place of the holes to compensate the negatively charged sulfonate
moieties on the PSS backbone [36]. As a consequence, the hole density reduces
and decreases the polymer conductivity and therefore lowers the current that
passes through the channel.
PEDOT:PSS is therefore a p-type semiconductor which has holes as charge
carriers and these holes are extremely mobile and in the presence of a voltage
drop across the polymer, the holes can easily move to carry charge. When the
polymer is de-doped, heavy (less mobile) cations from the electrolyte penetrate
the polymer and replaces the holes which decreases conductivity and subse-
quently reduces the current ﬂow through the polymer. The relevant electro-
chemical reaction of PEDOT:PSS subject to an electrolyte given in Equation
2.4 below:
PEDOT : PSS +M+ + e− ⇔ PEDOT +M : PSS (2.4)
whereM+ represents a cation present in the electrolyte that enters the polymer
ﬁlm [46]. PEDOT:PSS undergoes oxidation with an applied voltage greater
than 0.8 V and undergoes reduction with an applied voltage less than -0.8 V .
One of the main advantages of PEDOT:PSS is that it has the potential of
introducing a large number of carboxyl (-COOH) groups on the surface when
mixed with a modiﬁed bipolar carboxymethelated dextran (CMD) [47]. The
carboxyl groups are ideal for antibody immobilization through covalent bond-
ing using NHS/EDC or bioaﬃnity interactions. Antibodies are immobilized
onto PEDOT:PSS with the use of a buﬀer solution for 30 to 60 minutes to
allow for incubation and complete immobilization. Berezhetska et al. [47] dis-
covered that mixing pristine dextran (0.2% w/v) into the buﬀer solution, the
dextran acted as a blocking agent towards the non-speciﬁc adsorption of the
capture antibodies which increased the immobilization.
PEDOT:PSS is also extremely stable in aqueous conditions, allows for elec-
tronic and ionic ions transport, processable by a variety of methods and is
readily available [48]. Another advantage of PEDOT:PSS is that the electrical
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conductivity can also be further enhanced by mixing it with certain solutions.
Glycerol, a simple colorless polyol compound, is a popular conductivity en-
hancer because of its low toxicity, ready availability at low cost and ease of
fabrication and processing [47]. Other popular conductivity enhancers are
Dimethyl sulfoxide (DMSO) and Ethanol.
2.6.3 Immobilization Techniques
The immobilization of the antibodies onto the surface of the transducer is a
critical step in the construction of assays and immunosensors [49]. Some assays
and immunosensors require maximum sensitivity, while others require more
consistency or lower cost [50]. Many factors inﬂuence the eﬃciency of these
sensors, but the correct orientation of immobilized antibodies have become
critical for antigen detection. Many studies have shown that properly oriented
antibodies, with their binding sites well exposed to the solution phase, exhibit
higher binding eﬃciency [50]. The proper selection of linker molecules also
reduces non-speciﬁc binding.
The correct technique also indirectly determines the number of binding sites
available for antibody-antigen binding. A typical success rate of immobiliza-
tion techniques ranges from 20% - 80% [8]. Various antibody immobilization
approaches are available in literature with diﬀerent degrees of complexity, but
the three most common immobilization techniques used in immunosensors are:
adsorption, covalent bonding and non-covalent bonding.
Adsorption
Physical adsorption is the simplest, most straightforward and most frequently
used technique for protein immobilization [51]. Adsorption oﬀers rapid, min-
imal steps and minimal usage of chemical reagents, being some of the main
reasons for its popularity. The limitations of physical adsorption include un-
stable binding which leads to easy desorption of antibodies, no control over
random oriented antibodies and being prone to signiﬁcant loss of sensitivity
and functionality [49]. In ELISA tests, the capture antibodies are generally
adsorbed to the bottom the plate.
Covalent Bonding
A Covalent bond refers to the chemical (molecular) bond that involves the shar-
ing of electron pairs between atoms and the stable balance of forces between
the atoms are known as covalent bonding. Covalent bonding is irreversable
with a high immobilization density between the antibody and the functional
groups on the surface [51]. Covalent bonding is also extremely stable, ﬂexible
and exhibits a strong binding strength and low desorption from the surface
[49].
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During covalent bonding, it is common practice to immobilize amine (NH2)
terminated DNA probes (antibodies) with several functional groups such as
carboxyl (COOH), thiol (SH), aldehyde (CHO), sulfonic (SO3
−), epoxy and
isothiocyanate (NCS) groups, leading to highly speciﬁc attachments which
may prevent non-speciﬁc binding [49]. Some of the most popular covalent link-
age agents include gluteraldehyde, carbodiimide and succinimide. Although
covalent bonds are the strongest from of immobilization technique, they may
result in randomly oriented antibodies which decrease the availability of func-
tional active sites (paratopes) and decrease the overall eﬃciency [52].
Non-covalent Bonding
Research into the development of orientation-controlled immobilization tech-
niques have recently received considerable attention. An interesting solution to
this problem is to increase the number of functional antibodies by introducing
bioaﬃnity pairs which can bind to the Fc region of antibodies to optimize the
orientation. Aﬃnity refers to the degree to which a substance tends to com-
bine with another for which it has a natural preference. An antibody-antigen
pair is an example of an aﬃnity pair.
One of the most common and widely used bioaﬃnity immobilization ap-
proaches is the use of the biotin-streptavidin interaction. The binding aﬃnity
of biotin to streptavidin is the strongest non-covalent interaction known, with
a dissociation constant (KD) in the femtomolar range [49]. This interaction is
highly speciﬁc, has a rapid on-rate, highly resistant to changes in temperature
or pH, and is extremely robust and stable. This interaction, however, requires
multiple surface functionalization steps which increases the complexity, pro-
duction time and cost. The interaction between biotin and streptavidin can
be seen as a weight (biotin) and gravity (the aﬃnity interaction). The biotin
is bound to the Fc region of the antibody and the "gravitational forces" op-
timizes the orientation of the antibodies and the density of bound antibodies
[50].
2.6.4 Chemical Crosslinkers
As mentioned previously, chemical crosslinkers are vital to the immobiliza-
tion of antibodies. Ates et al. [51] compared two covalent and two bioaﬃn-
ity (non-covalent) antibody immobilization crosslinkers and compared each
crosslinker in respect to its capture eﬃciency and selectivity. These crosslinkers
are APTES, NHS/EDC, Glutaraldehyde and Streptavidin and are discussed
below.
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APTES
APTES ((3-Aminopropyl)triethoxysilane) is an aminosilane commonly used
for silanization, the covering of a surface with organofunctional alkoxysilane
molecules. Therefore APTES is used as a surface functionalizer to generate
a NH2 terminated monolayer after which the surface can be treated with a
carboxyl activation step before antibody immobilization [49].
NHS/EDC
NHS/EDC consists of two carbodiimide reagents namely N-hydroxysuccinimide
(NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and is a
commonly used coupling reagent to covalently bond carboxyl groups to amines
(NH2) terminated DNA probes (antibodies) [49]. Therefore NHS/EDC can
be utilized as the carboxyl activation step.
Glutaraldehyde
Gluteraldhyde is a frequently used bifunctional linker between amine function-
alized electrodes and NH2 terminated DNA probes to form covalent amide
bonds [49]. Gluteraldehyde can be used as a substitute for NHS/EDC to bind
carboxyl and amine groups. The main disadvantage of Gluteraldehyde that it
is extremely sensitive and can cause non-speciﬁc binding.
Streptavidin
As mentioned earlier, the non-covalent aﬃnity between streptavidin and biotin
is extremely high, nearly to a point of a covalent bond. Streptavidin is a large
tetrameric protein (with molecular weight of 70 kDa) which provides bind-
ing sites for four biotin molecules as illustrated in Figure 2.15. This complex
is commonly used to immobilize antibodies onto solid electrode surfaces(e.g
ELISA tests) [49]. This is done by conjugating the antibodies with a biotin
molecule and later introducing it to the streptavidin-coated substrate. Strep-
tavidin is commonly adsorbed to the substrates (e.g. ELISA wells) as it forms
a monolayer which increases the binding-eﬃciency of the biotin-streptavidin
complex.
Streptavidin Biotin-Streptavidin 
Complex
Biotin
Figure 2.15: Biotin-Streptavidin complex
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2.6.5 Antibody Conjugation Labels
A conjugated antibody refers to any antibody that is linked with a label to
provide a means of measurement for the desired signal. Conjugated labels
can either be conjugated to the primary antibody (direct detection) or to the
secondary antibody (indirect detection). It is also seen as an excellent alter-
native to using secondary antibodies, but it can also be used together with a
secondary antibody to amplify the signal or to produce a colored (ﬂuorescent)
readout to help with the detection of the target antigen. Other advantages of
directly labeled antibodies include fewer incubation and wash steps, increased
signal quality and better reproducibility. A wide variety of conjugation labels
or tags are available; however, the most commonly used conjugated tags utilize
enzymes or proteins such as Horseradish Peroxidase (HRP) or Alkaline Phos-
phatase (ALP). Other labels that can be used include dyes, Biotin, ﬂuorescent
proteins and gold nanoparticles. This section discusses some of the tags in
greater detail.
Horse Radish Peroxidase
Horseradish peroxidase (HRP) is an popular enzyme used to amplify photo-
metric (the measurement of light) signals in immunoassays by catalyzing the
conversion of chromogenic or chemiluminescent substrates for the detection of
target proteins. HRP enzymes are commonly utilized in ELISA tests and are
used as conjugates to determine the presence of the target protein or molecule.
HRP is ideal because it is smaller, more stable and less expensive than alter-
native enzymes such as Alkaline Phosphatase (ALP). Another chromogenic
substrate, Tetramethyl Benzidine (TMB), is used in conjunction with HRP.
TMB in its reduced form is colorless, but in the presence of HRP and H2O2,
the TMB is oxidized and turns blue which indicates the signal strength.
Biotin
Biotin is a water-soluble vitamin (also known as vitamin B7 or vitamin H) and
has a molecular weight of 2.4431 g/mol and chemical formula C10H16N2O3S.
Antibodies are generally conjugated (labeled) with Biotin through the binding
with available amine groups. The direct labeling of antibodies eliminates the
need for secondary reagents (e.g. HRP conjugated antibodies) in immunoas-
says, thus removing tedious extra incubation and wash steps in applications
such as ELISAs and Western Blotting.
Gold Nanoparticles
Gold nanoparticles (Au NP's) are extremely popular conjugation labels due to
their large surface areas, straightforward synthesis methods, good biocompati-
bility and optical properties when conjugated with antibodies. Gold nanopar-
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ticles are preferred for sandwich-type immunoassays because of the inherent
signal ampliﬁcation properties, enlarged dynamic range, improved sensitiv-
ity, stability an selectivity [53]. On-site signal ampliﬁcation is preferred over
hardware signal ampliﬁcation (e.g. operational ampliﬁers) as the latter induce
undesirable noise and interference in the signal, aﬀecting the immunosensor
accuracy and sensitivity.
2.6.6 Device Geometry and Structure
Despite the growing interest in OECTs, their device physics is not well under-
stood. Two critical considerations for the optimization of the device sensitivity
and ampliﬁcation eﬃciency, is channel geometry and the gate electrode ma-
terial and size. The device geometry also has a substantial inﬂuence on the
transistor speed and response times [39]. One unique characteristic of OECTs
is that the gate electrode does not have to be placed close to the channel area.
The reason for this is that the electrolyte increases the variability of possible
allowable device geometries such as planar device architectures [54].
The area ratio (AR) is deﬁned as the ratio between the channel area and the
gate area (AR = Ach/Ag) and is a critical parameter to take into consideration
when designing OTFTs and OECTs in particular. Cicoira et al. [54] evaluated
various area ratios for diﬀerent gate voltages and concluded that OECTs with
smaller area ratios (e,g. AR = 0.1) possessed the best current modulation
(|I − IO|/IO), lowest background signal and highest sensitivity. Hutter et al.
[39] discovered that thicker PEDOT:PSS layers and a smaller gap between the
gate and channel area, increased the drain current and sensitivity even further.
2.6.7 Substrate
The substrate not only serves as mechanical support but greatly aﬀects the
performance of OTFTs. The ideal substrate surface should be clean and have
low surface energy (the energy associated with the intermolecular forces at
the interface between the surface and the deposited material) [44]. Some fab-
rication techniques require the substrate to be hydrophobic (water resistant)
whereas other techniques require the substrate to by hydrophilic (water lov-
ing). The substrate itself should also be chemically resistant to some solvents,
where desired, to aid in the subsequent processes. Some popular substrates
used for OTFTs are glass, silicon wafers (Si/SiO2), plastic, metal foil and
paper (e.g. ﬁlm or photo paper).
2.6.8 Electrodes
The most commonly used materials for electrodes in OTFTs are Silver (Ag),
Platinum (Pt) and Gold (Au), where each material has its respective advan-
tages and disadvantages. Tarabella et al. [55] investigated the current mod-
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ulation in an OECT and found that the current modulation is larger with
silver gate electrodes in comparison to platinum gate electrodes. The interface
between the electrode and OSC is also extremely important in order to allow
for a simple and large charge injection area. The working electrodes are bio-
logically functionalized and should therefore be chosen to optimize the OTFT
characteristics and performance.
As mentioned earlier, the gate electrode modulates the current in the chan-
nel therefore it is essential to the operating principle of OTFTs [44]. The con-
ductivity of the gate electrode aﬀects the OTFT performance therefore much
attention should be paid to choosing to optimal material for the gate electrode.
According to Contat-Rodrig et al [56] the gate electrode should be larger than
the channel in order to exhibit higher current modulation and ampliﬁcation as
well as decreasing the area ratio.
2.6.9 Performance Criteria
To evaluate OTFT performance, it is important to understand the related
performance criteria in order to develop high-performance OTFTs.
Mobility
Mobility refers to the ability to move freely, therefore with respect to OTFTs,
mobility refers to the movement of charge carriers, where a higher mobility
provides a larger output current as the holes or electrons move more easily
[44]. When a thin OSC ﬁlm is used as the active layer, the mobility is af-
fected by a great number of factors such as charge injection, purity of OSC,
surface roughness of OSC-interfaces, charge trapping inside the OSC and ap-
plied voltages [44]. When a thick OSC ﬁlm is used, theoretically it should
result in a higher mobility as more charge carriers are present. As mentioned
in Section 2.6, upon the application of a positive gate voltage, ions penetrate
the electrically conducting polymer in a OECT causing a decrease in mobile
charge carriers resulting in a decrease in mobility and subsequently the channel
current.
Threshold Voltage
The threshold voltage (VT ) refers to the minimum gate-source voltage (VGS)
that is required to create a conducting path between the source and drain
terminals through the channel and therefore to switch the OTFT "on". High-
performance OTFTs always demand small threshold voltages, since the desir-
able operating voltages of OTFTs are less than 1 V [44]. OTFTs with small
threshold voltages are also ideal as this minimizes the power consumption of
OTFTs, which is important especially when used with portable devices pow-
ered with batteries. The threshold voltage is inﬂuenced by a number of factors
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such as the OSC mobility, OSC thickness, gate dielectrics and OSC-interfaces;
however, these can be ﬁne tuned and optimized during the device fabrication
process prior to any antibody immobilization.
Threshold voltage shifts are frequently reported in the literature. This
phenomenon is similar to that which occur during the application of a constant
gate voltage (VG) for an extended period of time[57]. This bias stress causes
instabilities that lead to either hysteresis or degradation. The direction of the
shift is such that a fully turned on OTFT is able to slowly turn itself oﬀ or
vice versa [57].
Sheet Resistance
The sheet resistance is the resistance between the source and drain terminals
due to the thin OSC layer prior to the addition of an aqueous medium and
is measured in ohm (Ω). Sheet resistance (RS), also referred to as contact
resistance (RC), is a critical ﬁgure-of-merit in developing high-performance
OTFTs, since a high sheet resistance degrades transistor mobility and impedes
device down-scaling for high-speed operation [44]. Modern MOSFETs have
sheet resistances of 0.1 Ω whereas the typical series resistances of OTFTs often
tend to be in the kΩ range.
Some of the main contributors to the sheet resistance are the OSC material
and design. The charge injection in OECTs occurs at the contact interface of
the electrolyte and the OSC, therefore a small injection area may limit injec-
tion eﬃciency and raise RS. Other factors that inﬂuence the sheet resistance
include OSC microstructure, OSC purity and the OSC ﬁlm thickness.
Hysteresis
Hysteresis is the unwanted eﬀect in which the OECT parameters (speciﬁcally
ID) depend on the applied gate voltage sweep range, direction and time. Hys-
teresis can also be described as irreversible electrical disabilities and should
ideally be minimized or eliminated. According to Xu et al. [44], hysteresis
is not a device parameter, however it reﬂects the device quality, stability and
reliability. The hysteresis eﬀect is veriﬁed using cyclic transfer or output char-
acteristics where the drain voltage (VD) is swept at speciﬁc gate voltages (VG)
resulting in varying forward and backward currents.
Lower backward sweep current hysteresis is very often attributed to charge
carrier trapping close to the channel interface, whereas higher backward sweep
current hysteresis is usually caused by mobile ions in the dielectric [57]. Hys-
teresis often depends on the sweep rate, the start and end voltage of the sweep,
the step width, the delay time, the hold time and the step delay time, therefor
it is extremely important to clearly deﬁne all these parameters in order to
compare diﬀerent OECTs [57].
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Transconductance
OECTs are characterized by the use of transfer curves which describe modula-
tion eﬀectiveness and the dependence of the drain current (ID) on applied gate
voltage (VG). The transconductance is represented by the ratio between the
change in drain current as a result of a change in gate voltage and is expressed
in Equation 2.5 below and is measured in siemens (S).
gm =
4ID
4VG (2.5)
The transconductance can also be calculated as the derivative of the trans-
fer curve in terms of the gate voltage. The transconductance is a proper indica-
tion whether an OECT will be able to operate as an immunosensor [48]. The
transconductance also evaluates the OECT performance, eﬃciency, current
modulation and ampliﬁcation eﬀectiveness [58]. High ampliﬁcation is impor-
tant to increase signal to noise ratios and to lower the detection limits and
increase sensitivity [42]. The transconductance also depends on the channel
geometry and biasing conditions and describes the performance of the device
at steady-state. According to Friedlein et al. [59] OECT transconductance
has a non-monotonic (unpredictable) dependence on the gate voltage which
means it decreases at both high and low gate voltages, depending on the ge-
ometry and fabrication technique. The transconductance is also dependent on
the materials used in the fabrication of the OECT.
Limit of Detection
The limit of detection (LOD), is deﬁned as the lowest concentration or quan-
tity that can be reliably detected with a given analytical method. The LOD
can also be determined by the signal-to-noise ratio which can be optimized by
decreasing the noise level in the measurement[38]. OTFT-based immunosen-
sors are commonly characterized based on the measurements of DC current
responses and should ideally be greater than 3 times higher than the noise lev-
els of the currents. One solution to this is to use AC measurements which can
alleviate noise by ﬁlter circuits which can lead to more stable data and better
signal-to-noise ratios. Wang et al [38] successfully investigated AC measure-
ments of OECT-based immunosensors to detect chemicals with lower LODs
by miniaturizing the channel area of the OECT to tens of micrometers.
Uniformity and Stability
High uniformity and stability are also important criteria of OTFT performance
and requires all of the preceding parameters to be almost identical for each
transistor. Therefore is it extremely important that the fabrication process of
the OTFTs is repeatable and robust. However for printed OTFTs, it proves to
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be a challenging task, as common varying factors that inﬂuence the repeata-
bility are: OSC deposition, surface treatments, printing-related variations in
ﬁlm thickness and misalignment issues [44]. Various articles in the litera-
ture discuss annealing temperatures and durations; however, this is diﬀerent
for each fabrication technique and material. Annealing removes residual sol-
vent,removes impurities, absorbs moisture and chemically stabilizes all ﬁlms
and their interfaces [44].
2.6.10 Organic Thin Film Transistor Considerations
Immense progress has been made in the past decade in the development of
OTFT-based immunosensors. OTFTs also have the ability to be manufac-
tured at low cost, deployed on ﬂexible substrates and can be disposable which
is ideal of low-cost point-of-care devices. Another ideal characteristic is the
possibility of tailoring organic material to ﬁt the desired application. OTFT-
based immunosensors also have the possibility of using printing techniques for
manufacturing as most of the materials are in a liquid form, e.g. silver or
gold nanoparticle ink for the electrodes, or PEDOT:PSS and P3HT for the
semiconductors.
The main concern regarding the development of OTFT-based immunosen-
sors remains the integration of the biological recognition element into or on
the semiconductor without compromising performance and durability [36]. An-
other concern is the fabrication process which is critical for highly sensitive and
accurate immunosensors.
2.7 Printed Immunosensors
Much progress has been made recently in developing methods for the additive
and roll-to-roll printing manufacturing of immunosensors. This was stimu-
lated by the ease of large-scale fabrication, low-cost, bio-compatible and envi-
ronmentally friendly methods [44]. Printing processes are versatile techniques
enabling the deposition of various inks and solutions (such as biomolecules,
polymers, solvents, etc.) onto diﬀerent types of substrates (such as polymers,
paper, glass, silicon, etc.) [58]. The ability to print high-performance OTFTs
directly onto a rigid or ﬂexible substrate could drastically simplify the fabri-
cation process to produce low cost POC devices.
There are two kinds of printing methods based on the printing character-
istics, namely direct-wiring printing (where patterning is done by ink ejec-
tion without contact) and transfer printing (where the patterned material is
transferred from a donor substrate to an acceptor substrate) [44]. Examples
of direct-wiring printing methods include inkjet printing, spray printing and
screen printing. Examples of transfer printing methods include gravure print-
ing, oﬀset printing, ﬂexography printing and laser printing. The two most
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popular methods are inkjet printing and screen printing and will be discussed
in detail in this section.
2.7.1 Inkjet Printing
Inkjet printing has recently received a fair amount of interest as method for
OTFT fabrication. Inkjet printing can produce high resolution prints and uses
ink that can be manufactured easily from a wide range of materials [44]. The
versatility of inkjet printing enables it to deposit almost any material that can
be formulated as a suspension, solution or dispersion in a liquid form. Inkjet
printing also facilitate the deposition on contact-sensitive materials due to the
absence of physical contact between the printhead and the substrate [60].
There are two types of inkjet printing technologies, namely the continuous
inkjet system and drop-on-demand (DOD) inkjet system; the latter being the
most commonly used technology. As the name suggests, continuous inkjet
printing uses a high-pressure pump that directs liquid ink from a reservoir
through a gun body and a microscopic nozzle, creating a continuous stream of
ink droplets while the printhead is moving. In these printers, a piezoelectric
crystal creates an acoustic wave as it vibrates within the gun body, causing
the stream of ink to break into droplets which are subjected to an electrostatic
ﬁeld created by a charging electrode as they form. The charged droplets passes
through an electrostatic ﬁeld and is deﬂected by piezoelectric elements that
either allow the droplets to fall on the substrate, or allow the droplets into a
recycling gutter for re-use.
Drop-on-demand inkjet printing is quite similar to continuous printing, but
instead of a continuous stream of ink droplets, droplets are only formed when
required. This is done by means of either thermal or piezoelectric excitation
inside the printhead. One of the main drawbacks of thermal printheads is
that it uses heat to form the droplets which can denature bio-material inks
and polymers. Piezoelectric printheads force small drops through the ﬁne
nozzles by pressure pulses generated by vibrating piezoelectric crystals [46].
Piezoelectric printheads do not apply heat to the ink [60]. Figure 2.16 shows
graphically the diﬀerent principles of operation of continuous and drop-on-
demand inkjet printing systems.
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Figure 2.16: Principle of operation of the a) continuous inkjet system and the
b) drop-on-demand inkjet printing system [61]
A major challenge of inkjet printing is the uneven surface morphology due
to the varying viscosities and drying times of the ink droplets known as the
coﬀee stain eﬀect. The coﬀee stain eﬀect leads to poor performance, poor
uniformity and uneven ﬁlms [44]. A solution to this is to use a co-solvent with
diﬀerent surface tension in order to counter the coﬀee stain eﬀect. Another
disadvantage of inkjet printing is the tendency of the printhead nozzles to clog
due inconsistent ink viscosity, heating, incorrect solution mixture, etc. Inks
with viscosities between 1 and 10 mPa.s are considered to be inkjet printable
[58]. Apart from these challenges, inkjet printing remains a popular printing
technique due to the low cost, resolution and versatility.
2.7.2 Screen Printing
Screen printing is another popular printing technique used for the fabrication
of OTFTs. Screen printing involves squeezing a specially prepared ink through
a mask (stencil) comprising a ﬁne mesh onto a substrate to form the desired
pattern [62]. This requires a more viscous ink compared to inkjet printing
[44]. The resolution is determined by the size of the mesh openings and spaces
between the openings. Screen printing is ideal for the development of multiple
layers and electrodes [44].
Screen printing holds some advantage over inkjet printing owing to the
ability of large scale production due to the printing speed. Figure 2.17 illus-
trates the principle of operation of screen printing and shows how the ink is
squeezed through the mask to form the pattern.
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Figure 2.17: Principle of operation of screen printing [63]
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Chapter 3
Design Speciﬁcations
This chapter presents the design speciﬁcations for the proposed immunosensor
with reference to the aims and objectives deﬁned in Section 1.2 as well as the
contribution of the thorough literature review in Chapter 2.
Structure and Materials:
 The immunosensor should have a three electrode structure to control the
ﬂow of the channel current with the use of an external electrode
 The immunosensor should be based on an OECT and include an con-
ducting polymer to facilitate the migration of ions
 The immunosensor should use PEDOT:PSS as conducting polymer
 The immunosensor should use Silver Nano-particle ink for the electrodes
to allow for current-ﬂow
 The substrate of the immunosensor should be paper to reduce the cost
and increase ease of fabrication
Fabrication:
 The immunosensor should be manufactured using an inkjet printer to
reduce cost
 The immunosensor should be annealed to remove moisture in the paper,
semiconductor and electrodes
Antibodies:
 The immunosensor should utilize a sandwich antibody conﬁguration to
increase the sensitivity and speciﬁcity towards the insulin protein
46
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 The immunosensor should employ high aﬃnity monoclonal antibodies
with diﬀerent clones to obtain the highest sensitivity and speciﬁcity
 Thorough antibody pairing tests should commence to verify the best
possible antibody pair
 The capture antibodies should be conjugated with Biotin to assist the
antibody orientation and successful immobilization
 The detection antibodies should be conjugated with gold nano-particles
for on-site signal ampliﬁcation
Immobilization:
 The surface of the immunosensor should be functionalized with Strepta-
vidin to aid antibody orientation and immobilization
 The Biotinylated antibodies should be adsorb to the streptavidin-coated
surface to reduce immobilization steps
Measurement:
 The immunosensor should undergo an electrical characterization before
any antibody immobilization to verify if the immunsensors function as
OECTs
 The immunosensor should be characterized and tested using voltages less
than 1 V to prevent oxidation or reduction
Performance:
 The control unfunctionalized immunosensor should have a sheet resis-
tance of no more than 20 Ω to increase the channel current
 The immunosensor sheet resistance should increase after the addition of
the antibodies
 The immunosensor should have a limit of detection of 8 µIU/ml (0.3
ng/ml)
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Chapter 4
Materials and Methods
This chapter presents all materials used during the duration of the project as
well as the methodologies and processes followed in order to obtain accurate
results.
4.1 Apparatus and Instrumentation
The apparatus that was used to supply the driving voltages and to measure
the desired voltages and currents was the National Instruments (NI) Compact-
DAQ USB Module chassis (cDAQ-9174) with a 32-Channel C Series Voltage
Input Module (NI-9205) and a 16-Channel C Series Voltage Output Module
(NI-9264). The apparatus was controlled by the NI LabVIEW 2015 Instru-
mentation Software to provide constant and periodically varying voltages to
the drain and gate electrodes.
A popular benchtop inkjet printer used to manufacture immunosensors is
the Dimatix Materials Printer DMP-2850 which trades for R800 000, which
is extremely expensive compared to the inkjet printer employed during this
project which was the household HP DeskJet InkAdvantage 4535 printer which
trades for only R1500 [64]. All OECT designs and layouts were designed in
Gimp 2.0 (an open-source raster graphics editor) with a resolution of 1200
pixels per inch (ppi) in order to print at the highest resolution.
4.2 Materials and Reagents
The materials and reagents used during this study is provided in Table 4.1,
as well as die company it was purchased from and respective datasheet loca-
tion. DMSO, Glycerol (99.5+% purity), SU1818 Photoresist and Phosphate
Buﬀer Saline (PBS) (pH 7.4) was donated by the Electrical and Electronic
Engineering Department of Stellenbosch University.
48
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4. MATERIALS AND METHODS 49
Table 4.1: Materials and Reagents used during the study
Material Purchased From Datasheet
Monoclonal Anti-Insulin Antibody (A1364) BioVision Appendix B
Monoclonal Anti-Insulin Antibody (A1365) BioVision Appendix C
Recombinant Human Insulin Protein (ab123768) Abcam Appendix D
PEDOT:PSS (Clevios PH1000) Heraeus Electronics Appendix E
Silver nanoparticle Ink (NBSIJ-MU01) Mitsubishi Paper Appendix F
Mills Limited
Mitsubushi Photopaper (NB-RC-3GR120) Mitsubishi Paper Appendix G
Mills Limited
Lightning Link Rapid Biotin Conjugation Kit Expedeon Appendix H
GOLD Conjugation Kit (ab154873) Abcam Appendix I
Puriﬁed Streptavidin (280302) BioLegend Appendix J
Bovine Serum Albumin (BSA), Fraction V Sigma-Aldrich Appendix K
4.3 Antibody Pairing Tests
The aim and objectives of the antibody pairing tests is to verify the best an-
tibody pair that would provide the highest antibody binding aﬃnity, widest
dynamic range (detectable concentrations) and most stable signal for the de-
tection of human insulin. These tests will also conﬁrm any reaction between
the antibodies and the target epitopes and also validate the dynamic range of
the antibody pair. The antibody pairing tests were performed at Synexa Life
Sciences on a 96-well ELISA microplate using a sandwich ELISA conﬁgura-
tion. This section discusses the antibody selection process, required reagents
and buﬀers used during the testing as well as the plate layout and methodology.
4.3.1 Antibody Selection
The two chosen antibodies for the ELISA tests are the Anti-Insulin Antibody
A1364 and A1365 from BioVision. These two speciﬁc antibodies were chosen
because they have the same manufacturer which already performed extensive
testing on order to compare the antibodies. These two antibodies are ideal for
in vitro diagnostic assay development as both antibodies are mouse monoclonal
which will result in the optimal speciﬁcity and sensitivity that is desired for
these tests.
According to the antibody datasheets ( Appendix B and C), the antibody
A1364 detects human insulin and slightly recognizes proinsulin, however it
has no cross-reactivity with C-peptide. The antibody A1365 detects human
Insulin and it has no cross-reactivity with neither Proinsulin or C-peptide. The
manufacturer have performed ELISA tests and recommends that the antibody
A1364 is used as the capture and the antibody A1365 is used as detection
antibody due to the nature of the cross-reactivity and the inﬂuence it will
have on the sensitivity.
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4.3.2 Antibody Pairing Reagents and Buﬀers
All the required reagents and buﬀers were prepared at Synexa Life Sciences
and are given in Table 4.2 below.
Table 4.2: In-house prepared reagents and buﬀers for the antibody pairing
tests
Reagents and buﬀers Preparation
Anti-Insulin A1364 Stock 1 mL Stock Solution (0.5 mg/mL)
Anti-Insulin A1365 Stock 1 mL Stock Solution (1.007 mg/mL)
Recombinant Insulin Protein Prepare 1 mL Protein Solution (add 5 mg
Solution Stock lyophilized powder to 1 mL PBS)
Anti-Insulin A1364 Solution Prepare 6 mL Anti-Insulin A1364 Solution
(Capture antibody Solution) (add 12 µL A1364 Stock to 5988 µL PBS)
Anti-Insulin A1365 Solution Prepare 6 mL Anti-Insulin A1365 Solution
(Capture antibody Solution) (add 6 µL A1365 Stock to 5994 µL PBS)
Wash Buﬀer Prepare 100 mL PBS-Tween (0.05%) Solution
(Add 0.5 mL Tween-20 to 999.5 mL PBS)
Assay Buﬀer Prepare 50 mL 1% BSA Solution
(Add 0.5 g BSA to 50 mL PBS)
Blocking Buﬀer Prepare 50 mL 3% BSA Solution
(Add 1.5 g BSA to 50 mL PBS)
Biotinylated Anti-Insulin A1364 Prepare 6 mL Biotinylated Anti-Insulin A1364
Solution (Detection antibody Solution) Solution in Assay Buﬀer
Biotinylated Anti-Insulin A1365 Prepare 6 mL Biotinylated Anti-Insulin A1365
Solution (Detection antibody Solution) Solution in Assay Buﬀer
Streptavidin-HRP Solution Prepare 1:200 dilution of
Streptavidin-HRP stock in Assay buﬀer
(Add 60 µL stock to 11940 µL Assay Buﬀer)
TMB Substrate Solution Prepare 1:1 dilution of
TMB Reagent stock in Assay buﬀer
(Add 13 µL stock to 12987 µL Assay Buﬀer)
Stop Solution 2N HCL Solution
4.3.3 Antibody Pairing Plate Layout
As mentioned earlier, the manufacturer recommends to use the antibody A1364
as the capture antibody and the antibody A1365 as the detection antibody,
however for the purpose of this study, it was chosen to test both combinations
(as recommended and vice versa). Figure 4.1 below illustrates the ELISA
plate layout for both combinations. For the rest of this report, the antibody
pair with the anti-insulin A1364 capture antibody (left in Figure 4.1a) will be
referred to as antibody pair 1 and the other pair (right in Figure 4.1a) will be
referred to as antibody pair 2.
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Anti-Insulin A1364 Anti-Insulin A1365 Anti-Insulin A1365 Anti-Insulin A1364
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Figure 4.1: ELISA plate layout for the a) capture antibodies and the b) de-
tection antibodies
In order to test the dynamic range of the antibody pairs, the recombinant
human-insulin protein solution was diluted in PBS into various concentra-
tions that were added to the ELISA plate using the standard ELISA protocol.
Figure 4.2 indicates the ELISA plate layout with the respective designed con-
centrations and wells. The chosen concentrations covers a wide dynamic range
in order to fully test the ability of these antibodies.
Concentrations:
1. Assay Buffer
2. 8 µg/mL
3. 4 µg/mL
4. 2 µg/mL
5. 1 µg/mL
6. 0.5 µg/mL
7. 0.25 µg/mL
8. 0.125 µg/mL
9. 0.0625 µg/mL
10. 0.031 µg/mL
11. 0.015 µg/mL
12. 7.8 ng/mL
13. 3.9 ng/mL
14. 1.9 ng/mL
15. 0.976 ng/mL
16. 0.488 ng/mL
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Figure 4.2: ELISA plate layout for the designed insulin concentrations
4.3.4 Antibody Pairing Methodology
The antibody pairing test were performed using a sandwich ELISA conﬁgura-
tion as shown in Figure 4.3 below.
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Streptavidin-HRP
TMB
Biotinylated Detection Antibody
Recombinant Insulin Protein
Detection Antibody
Bovine Serum Albumin (BSA)
Figure 4.3: Schematic illustration of the sandwich ELISA conﬁguration [49]
The ELISA process is extremely time consuming as each reagent and buﬀer
has to be prepared prior to any test as well as the required wash step between
each incubation step. The following general ELISA protocol was followed in
order to ensure successful antibody immobilization, protein incubation and
wash steps.
1. Prepare all necessary reagents and buﬀers as tabulated in Table 4.2
2. Add 100 µL/well of Capture Antibody Solution (A1364 and A1365, re-
spectively) to the relevant wells as illustrated in Figure 4.1
3. Incubate ELISA plate (sealed) overnight in the dark at 4 °C
4. Wash plate three times with 300 µL/well Wash Buﬀer using a microplate
washer and remove remaining Wash Buﬀer by inverting plate and blot
against clean paper towel
5. Add 300 µL Blocking Buﬀer to each well and incubate at 1 hour at room
temperature with gentle shaking at 350 rpm
6. Wash plate three times with 300 µL/well Wash Buﬀer using a microplate
washer and remove remaining Wash Buﬀer by inverting plate and blot
against clean paper towel
7. Add 100 µL/well of Recombinant Human Insulin Dilutions, QCs and
Blanks (PBS) to relevant wells
8. Incubate plate (sealed) for 1 hour at room temperature with gentle shak-
ing at 350 rpm
9. Wash plate three times with 300 µL/well Wash Buﬀer using a microplate
washer and remove remaining Wash Buﬀer by inverting plate and blot
against clean paper towel
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10. Add 100 µL/well of Biotinylated Detection Antibody Solution (A1364
and A1365, respectively) to relevant wells as illustrated in Figure 4.1
11. Incubate plate (sealed) for 1 hour at room temperature with gentle shak-
ing at 350 rpm
12. Wash plate three times with 300 µL/well Wash Buﬀer using a microplate
washer and remove remaining Wash Buﬀer by inverting plate and blot
against clean paper towel
13. Add 100 µL/well of Streptavidin-HRP Solution to relevant wells
14. Incubate plate (sealed) for 1 hour at room temperature with gentle shak-
ing at 350 rpm
15. Wash plate three times with 300 µL/well Wash Buﬀer using a microplate
washer and remove remaining Wash Buﬀer by inverting plate and blot
against clean paper towel
16. Add 100 µL/well TMB Substrate Solution to all the wells
17. Incubate plate (unsealed) for 30 minutes at room temperature with gentle
shaking at 350 rpm and check regularly to prevent over-development f
color
18. Add 50 µL/well of Stop Solution to all the wells
19. Read plate absorbance at 450 nm using an ELISA plate reader
4.4 Device Fabrication Procedure
The fabrication of the OECTs were performed at the Electrical and Electronic
Engineering Department of Stellenbosch University. The source and drain
electrodes were printed with silver nanoparticle ink (Appendix F) and the
gate electrode was cut from a sheet sterling silver. For the preparation of the
PEDOT:PSS ink, the Clevious PH1000 solution was mixed with water (60
wt.%), DMSO (5 wt.%) and Glycerol (5 wt.%) in order to obtain the correct
viscosity and conductivity. The viscosity could however not be measured due to
the lack of equipment. The PEDOT:PSS mixture was then sonicated in order
to remove any impurities and kept on a magnetic mixer to evenly distribute
particles and improve uniformity. A cross-sectional view of the fabricated
OECT is shown in Figure 4.4. The fabricated OECT serves as the basis for the
control OECTs (used for the electrical characterization) and the functionalized
OECTs (used for the ﬁnal insulin measurement tests).
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VG
Source Drain
Gate
VD
Acrylic Well
PEDOT:PSS
Photoresist
Silver
Paper Substrate
Figure 4.4: Cross-sectioned schematic diagram of the OECT and the wiring
system for device operation [38]
4.4.1 OECT Fabrication
The following procedure was followed in order to ensure repeatable functioning
OECTs:
1. Print silver source and drain electrodes on Mitsubishi paper using the
HP DeskJet InkAdvantage 4535 printer
2. Spincoat 1 mL of Photoresist-Actone mixture (1:4 wt.%) at 600 rpm for
30 seconds followed by 2000 rpm for 10 seconds onto the printed paper.
3. Place a 5 µl drop of PEDOT:PSS mixture over of interdigitated source
and drain electrodes with a pipette
4. Anneal sensors at 90 - 100 °C for 2 hours in an oven
5. Fix the Acrylic well to the substrate with the use of double-sided tape
4.4.2 Antibody Immobilization
The OECTs were biologically functionalized with the antibodies in order to
test its ability to act as immunosensors. The functionalization conﬁguration
is given in Figure 4.5 below.
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Streptavidin
Gold-NP Conjugated 
Detection Antibody
Biotinylated Capture Antibody
Bovine Serum Albumin (BSA)
Recombinant Insulin Protein
Figure 4.5: Schematic illustration of the sandwich OECT conﬁguration [49]
The reagents and buﬀers used for the immobilization and functionalization
of the antibodies and proteins onto the OECTs, are given in Table 4.3.
Table 4.3: In-house prepared reagents and buﬀers for ﬁnal immunoassay tests
Reagents and buﬀers Preparation
Biotynalated Anti-Insulin A1365 Stock Prepare 200 µL Biotinylated Anti-Insulin A1365
Stock using Lightning-Link Rapid Biotin
Conjugation Kit
Biotinylated Anti-Insulin A1365 Solution Prepare 600 µL of Biotynalated Anti-Insulin A1365
(Capture Antibody Solution) Solution (add 5 µL of Biotinylated Anti-Insulin
A1365 Stock to 595 µL Assay Buﬀer)
Recombinant Human-Insulin Solution Prepare 1 mL Insulin Protein Solution (add 5 mg
Stock lyophilized powder to 1 mL PBS)
Streptavidin Coating Solution Prepare 1 mL of Streptavidin Coating Solution
(Add 10 µL Puriﬁed Streptavidin to 990 µL PBS)
Gold Nanoparticle Conjugated Prepare 100 µL Gold nanoparticle Conjugated
Anti-Insulin A1364 Stock Antibodies using the ab154873 Gold
Conjugation Kit
Gold Nano-Particle Conjugated Prepare 500 µL Gold nanoparticle Conjugated
Anti-Insulin A1364 Solution Anti-Insulin A1364 Solution (add 100 µL Gold
(Detection Antibody Solution) Nanoparticle Conjugated Anti-Insulin A1364 Stock
to 400 µL PBS)
Wash Buﬀer Prepare 50 mL of PBS
Assay Buﬀer (50 mL) Prepare 1% BSA Solution
(Add 0.5 g BSA to 50 mL PBS)
Blocking Buﬀer (50 mL) Prepare 3% BSA Solution
(Add 1.5 g BSA to 50 mL PBS)
The following procedure was followed in order to successfully immobilize
the antibodies on the PEDOT:PSS layer of the OECT.
1. Prepare all necessary reagents and buﬀers listed in Table 4.3
2. Add 16 µL of Streptavidin Solution to each well
3. Incubate sensor (sealed) for 120 minutes 4 °C
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4. Wash sensors three times with 16 µL/well Wash Buﬀer by gently pipet-
ting up and down and remove remaining Wash Buﬀer by inverting sensor
and blot against clean paper towel
5. Add 16 µL of Biotinylated Capture Antibody Solution to each well
6. Incubate sensors (sealed) overnight in the dark at 4 °C
7. Wash sensors three times with 16 µL/well Wash Buﬀer by gently pipet-
ting up and down and remove remaining Wash Buﬀer by inverting sensor
and blot against clean paper towel
8. Add 16 µL Blocking Buﬀer to each well
9. Incubate sensors (sealed) for 60 minutes at room temperature (20 - 25
°C
10. Wash sensors three times with 16 µL/well Wash Buﬀer by gently pipet-
ting up and down and remove remaining Wash Buﬀer by inverting sensor
and blot against clean paper towel
11. Add 16 µL Recombinant Human Insulin Concentrations to relevant wells
12. Incubate sensors (sealed) for 60 minutes at room temperature (20 - 25
°C
13. Wash sensors three times with 16 µL/well Wash Buﬀer by gently pipet-
ting up and down and remove remaining Wash Buﬀer by inverting sensor
and blot against clean paper towel
14. Add 16 µL Gold Nano-Particle Conjugated Detection Antibody Solution
to relevant wells
15. Incubate sensors (sealed) for 60 minutes at room temperature (20 - 25
°C
16. Wash sensors three times with 16 µL/well Wash Buﬀer by gently pipet-
ting up and down and remove remaining Wash Buﬀer by inverting sensor
and blot against clean paper towel
4.5 Measurement Procedure
All measurements were performed using the NI DAQ (cDAQ-9174), Analog
to Digital Converter (ADC) Module (NI-9205), Digital to Analog Converter
(DAC) Module (NI-9264) and the NI LabView 2015 Instrumentation Software.
The measurement setup is shown in Figure 4.6. A 147 Ω resistor (RD) was
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connected in series with the drain electrode, a 148 Ω resistor (RG) was con-
nected in series with the gate electrode and the source electrode was connected
to ground as illustrated in Figure 4.7. The driving voltages (VDD and VGG)
were supplied via the DAC module. In order to obtain current measurements,
output and transfer characteristics, four ADC channels were used to measure
required voltages (VDD, VDS, VGG and VGS). The collected data was analyzed
with a custom Matlab Script in order to provide accurate graphs.
Figure 4.6: A picture of the measurement device and suspended gate electrode
VDD
VGG
VDS
VDD
VGG
VGS
G
S
D
Drain
Gate
SourceID
IG ID
IG
RG
RD
b)a)
Figure 4.7: Graphical illustration of the a) device setup and b) circuit layout
for the OECT tests [35]
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The formulas for calculating the drain and gate currents are given in Equa-
tion 4.1 and 4.2 below:
ID =
VDS − VDD
RD
(4.1)
IG =
VGG − VGS
RG
(4.2)
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Results
This section discusses the results obtained for the antibody pairing tests, the
OECT fabrication, OECT electrical characterization and lastly the ﬁnal func-
tionalized immunosensor tests. All the data was processed using Matlab, a
numerical computing environment, in order to prepare the graphs and results.
The Matlab script is given in Appendix M.
5.1 Antibody Pairing
All the antibody pairing tests were performed following the methodology and
protocol discussed in Section 4.3. Succeeding the preparation of the ELISA
tests, immobilizing the respective antibodies and adding the designed insulin
protein concentrations, the TMB Substrate Solution was added. The TMB
reacts with the HRP and produces a solid blue reaction product. Figure 5.1
shows the physical color change. It is clear that the antibody pair 2 produces
a more gradual color change compared to the almost saturated color change
on the left (antibody pair 1). Therefore antibody pair 1 can be said to be more
speciﬁc, however the antibody pair 2 could be more sensitive as any form of
insulin present generated a signiﬁcant signal.
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Figure 5.1: A picture of the color change during the antibody pairing tests for
the ELISA plate
After the addition of the sulfuric acid Stop Solution, the color changed to
yellow, enabling accurate measurement of the intensity at 450 nm using an
ELISA plate reader. Figure 5.2 and 5.3 below provides the generated graphs
for the optical density (OD) signals for the respective antibody pairs at the
designated concentrations.
Figure 5.2: ELISA test results for antibody pair 1 (Capture Antibody A1364)
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Figure 5.3: ELISA test results for antibody pair 2 (Capture Antibody A1365)
The results supports the hypothesis that the second antibody pair produces
a more gradual signal over the tested concentration range. By inspecting the
results for antibody pair 1, it can be seen that above 4 ng/ml, the signal
strength appears to be saturated which contributes to a single logarithmic
dynamic range (0.5 - 4 /ml). The second antibody pair provides a 3 logarithmic
dynamic range (from 10 ng/ml to 8 µg/ml) which is superior to that of the
antibody pair 1. It can be noted that the ELISA protocol is extremely time-
consuming and was performed over 2 days, giving impetus to the need for a
rapid POC immunosensor.
5.2 Analysis of Device Fabrication
A total of over 500 transistors were developed and tested with an extremely
low yield rate due to the poor repeatability and alignment of the inkjet printer.
However, after placing a drop of the PEDOT:PSS instead of printing the semi-
conductor, the yield rate rose to over 90% which increased the repeatability
and reproducibility. This resulted in more consistent transistors with regard
to sheet resistance and drain currents, and enabled the production of the ﬁnal
OECTs including the immobilized antibodies and functionalized protein.
A total of 40 OECTs were developed, handled and stored under the same
conditions: 8 were left unfunctionalized to serve as controls, 4 were immobilized
with capture antibodies and the other 28 were immobilized with Biotinylated
capture antibodies and gold nanoparticle conjugated detection antibodies to-
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gether with the designed insulin concentrations. This section discusses the
analysis of the 8 fabricated control OECTs.
5.2.1 Silver Electrodes
The dimensions (in µm) of the interdigitated silver electrodes and uniform
gaps are shown in Figure 5.4. The channel area (the white space between the
electrodes) is therefore calculated to be 1.11 mm2. The size of the suspended
gate electrode that was in contact with the PBS solution was roughly 2 x 3
mm, which resulted in an area ratio of 0.18.
200
300
100
1400
400
Figure 5.4: Interdigitated electrode design dimensions of the OECT
Two magniﬁcation photos of separate printed silver electrodes are shown
in Figure 5.5. Figure 5.5a illustrates less eﬀective printed electrodes as can
be seen from the number of holes in the silver, whereas Figure 5.5b illustrates
superior printed silver electrodes. The holes can be attributed to a number of
factors such as clogged nozzles, inaccurate print speeds, incorrect viscosities,
ambient temperatures, etc. Due to the nature of the individual drops, it is
extremely diﬃcult to measure the actual ﬁlm thickness.
b)a)
Figure 5.5: A microscopic picture of a) less eﬀective printed silver electrodes
and b) superior printed silver electrodes
Figure 5.6 illustrates the diﬀerence in printing quality before and after
replacing a clogged printhead. Less eﬀective printed electrodes negatively af-
fect the sheet resistance, ampliﬁcation capabilities and responsiveness of the
OECT.
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b)a)
Figure 5.6: A picture of the printing quality of a) less eﬀective printed silver
electrodes before and b) superior printed silver electrodes after the replacement
of a printhead having clogged nozzles
The ﬁnal printed source and drain electrodes are shown in Figure 5.7a
below.
5.2.2 Semiconductor Characteristics
The semiconductor plays and vital role in order to obtain good electrical con-
tact between the source and drain electrodes. The eﬀectiveness of the semi-
conductor is also inﬂuenced by the fabrication technique. For inkjet printing,
it is common practice to print multiple layers of semiconductor ink on top of
one another to obtain the desired channel thickness. Here, the PEDOT:PSS
layer could however not be printed due to misalignment issues caused by the
low-cost printer. The solution was to drop a 5 µl drop of PEDOT:PSS onto the
interdigitated electrodes (shown in Figure 5.7b) instead of printing the semi-
conductor. This resulted in higher mobility and decreased sheet resistance
due to the increased layer thickness. Table 5.1 shows the variation of sheet
resistances of the fabricated functionalized and unfunctionalized OECTs.
b) c)a)
Figure 5.7: A picture of the manufactured a) spin coated electrodes, b) 5 µl
PEDOT:PSS Drop and c) the attached acrylic well
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Table 5.1: Sheet resistance measurements for unfunctionalized OECTs, OECTs
immobilizaed with capture antibodies and completely functionalized OECTs
Developed OECT Sheet Resistance
Control (Unfunctionalized) 7.05 Ohm
Control (Only Capture Ab) 8.33 Ohm
Concentration 1 (2000 µg/ml) 9.98 Ohm
Concentration 2 (1000 µg/ml) 10.4 Ohm
Concentration 3 (500 µg/ml) 11.65 Ohm
Concentration 4 (250 µg/ml) 12.63 Ohm
Concentration 5 (125 µg/ml) 10.28 Ohm
Concentration 6 (62.5 µg/ml) 12.85 Ohm
Concentration 7 (31.25 µg/ml) 11.95 Ohm
It is clear from Table 5.1 that the sheet resistance increased after the im-
mobilization of the streptavidin and biotinylated capture antibodies as well
as the addition of the insulin protein concentrations and gold-nanoparticle
conjugated detection antibodies.
5.3 Measurement Device Validation
The NI CompactDAQ and Modules together with the customized LabVIEW
software was validated using a LND150 N-Channel Depletion-Mode MOSFET.
The LND150 MOSFET is a N-channel MOSFET which uses electrons as the
mobile charge carriers, compared to holes in p-channel OECTs which there-
fore required positive drain voltages. Figure 5.8 below illustrates the output
characteristics of the LND150 MOSFET. Compared to the supplied output
characteristics curve given in the datasheet (Appendix L) the results corre-
sponds closely which shows shows that the measurement device is functioning
as desired.
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 5. RESULTS 65
Figure 5.8: Output characteristics (ID versus VD) of an LND150 N-Channel
MOSFET under gate voltages (VG) varying from -0.6 to 0.6 V and sweeping
VD from 0 to 4 V
5.4 OECT Electrical Characterization
For electrical characterization, a 20 µl drop of phosphate buﬀer saline (PBS)
solution was put on the surface of the PEDOT:PSS layer, inside the acrylic
well. The Ag gate (a strip of sterling silver) was suspended from the top
to make contact with the PBS droplet (refer to Figure 4.6). The output
characteristics were recorded by sweeping VD voltage from 0 V to -0.8 V and
the gate voltage was incrementally switched from 0.4 V to 0.7 V in steps of
0.05 V. Figure 5.9 shows the output characteristics (ID versus VD).
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Figure 5.9: Output characteristics (ID versus VD) of an OECT under gate
voltages (VG) varying from 0.4 to 0.7 V and sweeping VD from 0 to -0.8 V
The OECTs were biased at a constant VD = -0.4 V and VG = 0.4 V in
order to test the accuracy of the sensor at a ﬁxed biased point. From Figure
5.9, when biased at the above mentioned values it should result in a drain
current of 1.9 mA. Figure 5.10 demonstrates the response of the OECTs after
30 seconds at the biased point. It is clear that the current settles at 1.926 mA
after 20 seconds, which is a typical settling time of OECTs due to the slow
transfer rate of ions.
Figure 5.11 illustrates the transfer characteristic (ID versus VG) and result-
ing transconductance (gm versus Vg) for the OECT biased at VD equals -0.4 V
and sweeping VG from 0.7 down to 0.1 V.
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Figure 5.10: OECT response curve (ID versus Time (s)) biased at a gate
voltage (VG) of 0.4 V and a drain voltage (VD) of -0.4 V
Figure 5.11: Transfer characteristic (blue line, ID versus VG) and resulting
transconductance (red line, gm versus VG ) derived from mathematical diﬀer-
ential biased at VD = -0.4 V
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The hysteresis output curves of an OECT under gate voltages (VG) varying
from 0.4 to 0.7 V and sweeping VD from 0 to -0.8 V is given in Figure 5.12. It
can clearly be noted that the backward sweep current is lower than the forward
sweep current, which is caused by the charge carrier trapping at the channel
interface.
Figure 5.12: Hysteresis output curves (ID versus VDS) of an OECT under gate
voltages (VG) varying from 0.4 to 0.7 V and sweeping VD from 0 to -0.8 V
5.5 Final Immunosensor tests
After the immobilization and functionalization of the antibodies and insulin
proteins, the OECTs now function as immunosensors. The PBS containing the
varying recombinant human insulin concentrations were prepared and immo-
bilized prior to the measurements. The transfer characteristics measurements
were carried out by sweeping VG from 1 V down to 0 V and biasing VD at
-0.4 V. Figure 5.13 shows the immunosensor transfer curves at the diﬀerent
designed insulin concentrations ranging from 31.25 ng/ml to 2000 ng/ml.
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Figure 5.13: VG dependent transfer characteristics (ID versus VG, VD = -0.4
V) of OECTs functionalized with the designed insulin concentrations
It is clear from Figure 5.13 that the addition of the antibodies, blocking
buﬀer and insulin proteins resulted in a decrease in channel current as the
insulin concentration increased. Since the transconductance (gm) is a function
of the eﬀective gate voltage (V effg ), the transconductance will show a horizontal
shift due to the addition of an insulin concentration. Figure 5.15 illustrates
this horizontal shift in the transconductance after the addition of insulin at a
concentration of 500 ng/ml proving that the sensors in fact function as OECTs.
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Figure 5.14: VG dependent transconductance shift(gm versus VG, VD = -0.4
V) of an OECT measured in PBS solution (pH = 7.4) before and after the
addition of insulin with the concentration of 500 ng/mL
For comparison, the diﬀerent transfer curves for the functionalized and
unfunctionalized OECTs are given in Figure 5.15. It is clear that there is
also a horizontal shift caused by the change in eﬀective gate voltage due to
the addition of insulin concentrations. It is also clear that the addition of
only antibodies and the insulin concentrations, cause the threshold voltage to
decrease which is expected with OECTs. The threshold voltage decreased from
roughly 0.85 V (for unfunctionalized OECTs) to 0.7 V (for OECTS with insulin
concentrations added) resulting in lower operating voltages as the necessary
turn-on voltage has decreased.
In order to verify the limit of detection (LOD) and sensitivity of the fab-
ricated immunosensors, the ﬁnal tests involved biasing the immunosensors at
VG at 0.4 V and VD at -0.4 V and measuring the respective drain currents (ID)
after 30 seconds at the various insulin concentrations. Figure 5.16 provides the
resulting current versus concentration (logarithmic) results that can be used as
an immunosensor characterization curve. This characterization curve clearly
shows an exponential regression line, to a certain degree, gained from the drain
current values at the respective concentrations. The fabricated immunosensors
exhibit great sensitivity towards the immobilizaiton and functionalization of
proteins and antibodies. The immunosensors also display excellent selectivity
for the designed concentrations and provides a wide dynamic range. This pro-
vides a proper alternative to the conventional immunoassays and could assist
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Figure 5.15: VG dependent transfer characteristics (ID versus VG, VD = -0.4
V) of functionalized and unfunctionalized OECTs
in the measurement and control of diabetes to prevent or eliminate the extreme
health complications.
Figure 5.16: Immunosensor characterization curve for the designed concentra-
tions
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Chapter 6
Discussion and Conclusion
This thesis presented the development of a rapid immunosensor for the quan-
tiﬁcation of insulin based on a paper-based inkjet printed OECT. The proposed
immunosensor is inexpensive compared to current methods of insulin measure-
ment due to the use of a paper substrate and a low-cost inkjet printer. This
methodology reduces fabrication costs and improves the ability for large-scale
fabrication. The immunosensor is highly sensitive and speciﬁc towards in-
sulin due to the use of two high aﬃnity monoclonal antibodies in a sandwich
conﬁguration.
The developed immunosensor presented favourable sheet resistances of 7
- 12 Ω, which was much lower than the designed speciﬁcation (20 Ω). The
immunosensor also exhibited very few hysteresis which is highly desirable for
this type of sensors. A high transconductance was achieved through the use of
top-quality materials and device geometry. The limit of detection was 31.25
ng/ml that does not meet the desired 0.3 ng/ml. This was attributed to the
limitations of the antibody pair as observed during the antibody testing.
One of the major limitations of this research study was the poor alignment
observed by the inkjet printer, rendering it impossible to print multiple layers
of the semiconductor on top of each other and led to the substitution of the
printed layer for a drop of the semiconductor. Further research and work
into highly accurate low-cost inkjet printers would make a big contribution to
this technology. The oxidation of the gate electrode posed a limitation and
required the use of the acrylic well and external gate electrode as the printed
gate electrode dissolved due to the applied voltages. The ﬁnal major limitation
was caused by PBS seepage through the paper substrate which resulted in a
short circuit between the source and drain electrodes. This was solved after
the addition of the acrylic well that possessed an inner surface area smaller
than the surface area of the semiconductor drop preventing the PBS to seep
past the drop into the paper.
This study provided an inexpensive and innovative solution to quantify
insulin which can be manufactured using a low-cost household inkjet printer.
This would be extremely valuable for third world countries as it would be
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inexpensive, readily available and provide better treatment outcomes for di-
abetic patients that do not have direct access to health-care facilities. The
succeeding point-of-care device will also aid the distinguish between type 1
and type 2 diabetes without the need for sophisticated equipment i.e. liquid
chromatography-tandem mass spectrometry.
Other suggestions for future work include optimizing the device geometry
for even higher transconductances, sourcing of appropriate materials for the
electrodes to prevent oxidation, and ﬁnally the use of alternative materials for
the substrate such as ceramic or plastics to prevent seepage. The proposed
immunosensor met all other design speciﬁcations. The ﬁndings in this thesis is
in agreement with related research in this ﬁeld and permits future development
of a point-of-care device which can be used for rapid monitoring of insulin.
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PRINCIPLE
INTENDED USE
The Access Ultrasensitive Insulin assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative
determination of insulin levels in human serum and plasma (EDTA) using the Access Immunoassay Systems.
SUMMARY AND EXPLANATION
Insulin is a hormone secreted by the beta cells of the pancreas. Insulin regulates the uptake and utilization of glucose,
and is also involved in the regulation of protein synthesis and triglyceride storage.1,2,3 An increase in the amount of
glucose in circulation stimulates insulin secretion. Insulin in turn stimulates the uptake of glucose into the tissues and
inhibits the breakdown of glycogen in the liver. As the glucose level comes back to baseline so does insulin.
One of insulin's primary clinical uses is in the diagnosis and management of diabetes mellitus, a disease arising when
glucose is not adequately taken up into the tissues. The result is chronic hyperglycemia. Diabetes can have severe
complications including renal failure, heart disease, nerve damage, blindness, and gangrene. Severe hyperglycemic
episodes can cause ketoacidosis and coma.
Diabetes has been divided into 2 major categories based on the secretion of insulin. The first is insulin dependent
diabetes mellitus (IDDM) or Type I diabetes. It is brought on by the autoimmune destruction of the insulin secreting
beta cells in the pancreas.4 Insulin secretion gradually declines to an insignificant level as ultimately all beta cells are
destroyed. The patient must receive insulin injections in order to survive.
The second category is non-insulin dependent diabetes mellitus (NIDDM) or Type II. This disorder arises by an entirely
different mechanism. Here, the beta cells can still secrete insulin but the body has developed resistance to the hormone.3
When the concentration of glucose in circulation rises, the insulin response is slow and of insufficient magnitude. As the
disease progresses more and more insulin may be required to obtain the same level of glucose control. The patient may
need to be placed on drugs which stimulate insulin secretion or be supplemented with insulin, depending on their degree
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of glucose control. Type II diabetes is associated with genetic factors, obesity, sedentary life-style, and other unknown
factors. It can often be controlled by proper diet and adequate exercise.
The measurement of insulin is used in the following investigations:
• Diagnosis of diabetes:
Insulin levels under basal conditions or after glucose administration are useful for assessing the ability of the pancreas
to secrete insulin. Insulin levels are normally low in patients with insulin-dependent diabetes mellitus (IDDM) and are
normal or elevated in patients with non-insulin dependent diabetes mellitus (NIDDM).
• Early detection of diabetes:
The insulin response to the administration of glucose may be blunted well before the onset of clinical manifestations.
• Follow-up and stabilization of insulin-treated diabetics:
Insulin assays can be useful at the onset of insulin therapy to evaluate the duration of action of various insulin
preparations.
• Predicting complications of Type II diabetes (NIDDM):
The persistent elevation of insulin is a risk factor for the development of coronary disease.5
• Diagnosis of insulinoma:
Pancreatic beta-cell tumors may produce a state of hyperinsulinism leading to hypoglycemia.6
METHODOLOGY
The Access Ultrasensitive Insulin assay is a simultaneous one-step immunoenzymatic (“sandwich”) assay. A sample is
added to a reaction vessel along with mouse monoclonal anti-insulin alkaline phosphatase conjugate and paramagnetic
particles coated with mouse monoclonal anti-insulin antibody.7,8,9 The serum or plasma insulin binds to the antibody
on the solid phase, while the conjugate reacts with a different antigenic site on the insulin molecule. After incubation in
a reaction vessel, materials bound to the solid phase are held in a magnetic field while unbound materials are washed
away. Then, the chemiluminescent substrate Lumi-Phos* 530 is added to the vessel and light generated by the reaction
is measured with a luminometer. The light production is directly proportional to the concentration of insulin in the sample.
The amount of analyte in the sample is determined from a stored, multi-point calibration curve.
SPECIMEN
SPECIMEN COLLECTION AND PREPARATION
1. Serum and plasma (EDTA) are the recommended sample types and should not be used interchangeably.
Literature has indicated that differences in insulin levels may be seen for some individual matched serum and
plasma samples.10,11,12 Therefore, each laboratory should consistently use either serum or plasma for patient
care or research. Use of a single sample type will ensure proper insulin interpretations for those samples that are
tracked over time. Each laboratory should determine the acceptability of its own blood collection tubes and serum
separation products. Variations in these products may exist between manufacturers and, at times, from lot-to-lot.
2. Observe the following recommendations for handling, processing, and storing blood samples:13
• Collect all blood samples observing routine precautions for venipuncture.
• Allow serum samples to clot completely before centrifugation.
• Keep tubes stoppered at all times.
• Physically separate serum or plasma from contact with cells as soon as possible.
• Store samples tightly stoppered at room temperature (15 to 30°C) for no longer than eight hours.
• If the assay will not be completed within eight hours, refrigerate the samples at 2 to 8°C.
• If the assay will not be completed within 24 hours, or for shipment of samples, freeze at -20°C or colder.
• Thaw samples only once.
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3. Use the following guidelines when preparing specimens:
• Ensure residual fibrin and cellular matter has been removed prior to analysis.
• Follow blood collection tube manufacturer's recommendations for centrifugation.
4. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products.
Variations in these products may exist between manufacturers and, at times, from lot-to-lot.
5. Do not use hemolyzed samples, as hemolysis releases enzymes which degrade insulin.14
REAGENTS
PRODUCT INFORMATION
Access Ultrasensitive Insulin Reagent Pack
Cat. No. 33410: 100 determinations, 2 packs, 50 tests/pack
• Provided ready to use.
• Store upright and refrigerate at 2 to 10°C.
• Refrigerate at 2 to 10°C for a minimum of two hours before use on the instrument.
• Stable until the expiration date stated on the label when stored at 2 to 10°C.
• Stable at 2 to 10°C for 28 days after initial use.
• Signs of possible deterioration are a broken elastomeric layer on the pack or control values out of range.
• If the reagent pack is damaged (i.e., broken elastomer), discard the pack.
• All antisera are polyclonal unless otherwise indicated.
R1a: Mouse monoclonal anti-insulin coupled to paramagnetic particles, TRIS buffer, bovine serum
albumin (BSA) matrix, < 0.1% sodium azide, and 0.1% ProClin** 300.
R1b: Mouse monoclonal anti-insulin conjugated to bovine alkaline phosphatase, TRIS buffer, BSA
matrix, < 0.1% sodium azide, and 0.1% ProClin 300.
R1c: Mouse IgG in HEPES buffer, BSA matrix, < 0.1% sodium azide, and 0.5% ProClin 300.
**ProClin™ is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.
WARNING AND PRECAUTIONS
• For in vitro diagnostic use.
• Patient samples and blood-derived products may be routinely processed with minimum risk using the procedure
described. However, handle these products as potentially infectious according to universal precautions and good
clinical laboratory practices, regardless of their origin, treatment, or prior certification. Use an appropriate disinfectant
for decontamination. Store and dispose of these materials and their containers in accordance with local regulations
and guidelines.
• For hazards presented by the product refer to the following sections: REACTIVE INGREDIENTS, GHS HAZARD
CLASSIFICATION and EU HAZARD CLASSIFICATION.
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REACTIVE INGREDIENTS
CAUTION
Sodium azide preservative may form explosive compounds in metal drain lines.
See NIOSH Bulletin: Explosive Azide Hazard (8/16/76).
To avoid the possible build-up of azide compounds, flush wastepipes with
water after the disposal of undiluted reagent. Sodium azide disposal must be in
accordance with appropriate local regulations.
GHS HAZARD CLASSIFICATION
Insulin PMP (Compartment
R1a)
WARNING
H317 May cause an allergic skin reaction.
P280 Wear protective gloves, protective clothing and
eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical
advice/attention.
P362+P364 Take off contaminated clothing and wash it before
use.
reaction mass of: 5-chloro-2-methyl-4-isothiazolin
-3-one [EC# 247-500-7] and
2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1)
< 0.05%
Insulin Conjugate
(Compartment R1b)
WARNING
H317 May cause an allergic skin reaction.
P280 Wear protective gloves, protective clothing and
eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical
advice/attention.
P362+P364 Take off contaminated clothing and wash it before
use.
reaction mass of: 5-chloro-2-methyl-4-isothiazolin
-3-one [EC# 247-500-7] and
2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1)
<0.05%
Insulin Blocker
(Compartment R1c)
WARNING
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H317 May cause an allergic skin reaction.
H402 Harmful to aquatic life.
P273 Avoid release to the environment.
P280 Wear protective gloves, protective clothing and
eye/face protection.
P333+P313 If skin irritation or rash occurs: Get medical
advice/attention.
P362+P364 Take off contaminated clothing and wash it before
use.
Ethoxylated alkyl alcohol 0.1 - 0.5%
reaction mass of: 5-chloro-2-methyl-4-isothiazolin
-3-one [EC# 247-500-7] and
2-methyl-4-isothiazolin-3-one [EC# 220-239-6](3:1)
<0.05%
Safety Data Sheet is available at techdocs.beckmancoulter.com
EUROPEAN HAZARD CLASSIFICATION
Insulin PMP (Compartment R1a) Xi;R43
R43 May cause sensitization by skin contact.
S28 After contact with skin, wash immediately with
plenty of soap and water.
S37 Wear suitable gloves.
Insulin Conjugate (Compartment R1b) Xi;R43
R43 May cause sensitization by skin contact.
S28 After contact with skin, wash immediately with
plenty of soap and water.
S37 Wear suitable gloves.
Insulin Blocker (Compartment R1c) Xi;R43
R43 May cause sensitization by skin contact.
S28 After contact with skin, wash immediately with
plenty of soap and water.
S37 Wear suitable gloves.
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MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT
1. Access Ultrasensitive Insulin Calibrators
Provided at zero and approximately 1.0, 10, 50, 150 and 300 µIU/mL
(7.0, 70, 350, 1,050 and 2,100 pmol/L).
Cat. No. 33415
2. Quality Control (QC) materials: commercial control material.
3. Access Sample Diluent A
Vial Cat. No. 81908
Diluent Pack Cat. No. A79783 (For use with the UniCel DxI system onboard dilution feature.)
4. Access Substrate
Cat. No. 81906
5. Access Wash Buffer II, Cat. No. A16792
UniCel DxI Wash Buffer II, Cat. No. A16793
EQUIPMENT AND MATERIALS
R1 Access Ultrasensitive Insulin Reagent Packs
CALIBRATION
CALIBRATION INFORMATION
An active calibration curve is required for all tests. For the Access Ultrasensitive Insulin assay, calibration is required
every 28 days. Refer to the appropriate system manuals and/or Help system for information on calibration theory,
configuring calibrators, calibrator test request entry, and reviewing calibration data.
QUALITY CONTROL
Quality control materials simulate the characteristics of patient samples and are essential for monitoring the system
performance of immunochemical assays. Because samples can be processed at any time in a “random access”
format rather than a “batch” format, quality control materials should be included in each 24-hour time period.15 Include
commercially available quality control materials that cover at least two levels of analyte. More frequent use of controls
or the use of additional controls is left to the discretion of the user based on good laboratory practices or laboratory
accreditation requirements and applicable laws. Follow manufacturer's instructions for reconstitution and storage. Each
laboratory should establish mean values and acceptable ranges to assure proper performance. Quality control results
that do not fall within acceptable ranges may indicate invalid test results. Examine all test results generated since
obtaining the last acceptable quality control test point for this analyte. Refer to the appropriate system manuals and/or
Help system for information about reviewing quality control results.
TESTING PROCEDURE(S)
PROCEDURAL COMMENTS
1. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up,
principles of operation, system performance characteristics, operating instructions, calibration procedures,
operational limitations and precautions, hazards, maintenance, and troubleshooting.
2. Mix contents of new (unpunctured) reagent packs by gently inverting pack several times before loading on the
instrument. Do not invert open (punctured) packs.
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3. Use twenty (20) µL of sample for each determination in addition to the sample container and system dead volumes.
Use fifty (50) µL of sample in addition to the sample container and system dead volumes for each determination
run with the DxI system onboard dilution feature. Refer to the appropriate system manuals and/or Help system for
the minimum sample volume required.
4. The system default unit of measure for sample results is µIU/mL. To change sample reporting units to the
International System of Units (SI units), pmol/L, refer to the appropriate system manuals and/or Help system. To
manually convert concentrations to the International System, multiply µIU/mL by multiplication factor 7.0.
PROCEDURE
Refer to the appropriate system manuals and/or Help system for information on managing samples, configuring tests,
requesting tests, and reviewing test results.
RESULTS INTERPRETATION
Patient test results are determined automatically by the system software using a smoothing spline math model. The
amount of analyte in the sample is determined from the measured light production by means of the stored calibration
data. Patient test results can be reviewed using the appropriate screen. Refer to the appropriate system manuals and/or
Help system for complete instructions on reviewing sample results.
REPORTING RESULTS
EXPECTED RESULTS
1. Each laboratory should establish its own reference ranges to assure proper representation of specific populations.
2. Sera from 67 healthy fasting subjects were assayed to establish an expected range. A non-parametric estimate at
the 95% confidence level yields the following range:
Units Normal Range
µIU/mL 1.9-23
pmol/L 13.0-161
PROCEDURAL NOTES
LIMITATIONS
1. Samples can be accurately measured within the analytic range of the lower limit of detection and the highest
calibrator value (approximately 0.03-300 µIU/mL [0.21-2,100 pmol/L]).
• If a sample contains less than the lower limit of detection for the assay, report the results as less than that value
(i.e., < 0.03 µIU/mL [< 0.21 pmol/L]). When the DxI system onboard dilution feature is used, the system will
report results as less than 255 µIU/mL (1,785 pmol/L).
• If a sample contains more than the stated value of the highest Access Ultrasensitive Insulin Calibrator (S5),
report the result as greater than that value (i.e. > 300 µIU/mL [> 2,100 pmol/L]). Alternatively, dilute one volume
of sample with 9 volumes of Access Ultrasensitive Insulin Calibrator S0 (zero) or Access Sample Diluent A.
Refer to the appropriate system manuals and/or Help system for instructions on entering a sample dilution in a
test request. The system reports the results adjusted for the dilution. The DxI system onboard dilution feature
automates the dilution process, using one volume of sample with 9 volumes of Access Sample Diluent A, allowing
samples to be quantitated up to approximately 3,000 µIU/mL (21,000 pmol/L). The system reports the results
adjusted for the dilution.
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2. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the patient
sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic
procedures utilizing immunoglobulins or immunoglobulin fragments may produce antibodies, e.g. HAMA, that
interfere with immunoassays. Additionally, other heterophile antibodies such as human anti-goat antibodies may
be present in patient samples.16,17
Such interfering antibodies may cause erroneous results. Carefully evaluate the results of patients suspected of
having these antibodies.
3. The Access Ultrasensitive Insulin results should be interpreted in light of the total clinical presentation of the patient,
including: symptoms, clinical history, data from additional tests and other appropriate information.
4. Patients on insulin therapy are prone to the development of anti-insulin antibodies. These antibodies may interfere
with the assay.18,19,20,21,22
PERFORMANCE CHARACTERISTICS
PERFORMANCE CHARACTERISTICS
METHODS COMPARISON
A comparison of 153 serum insulin values using the Access Ultrasensitive Insulin assay on the Access Immunoassay
system and a commercially available immunoassay kit gave the following statistical data:
n
Range of
Observations
(µIU/mL) Intercept (µIU/mL) Slope
Correlation
Coefficient
(r)
153 1.4-219 -0.42 0.88 0.996
A comparison of 59 values obtained by assaying clinical samples of serum and plasma (EDTA) using the Access
Ultrasensitive Insulin assay kit on the Access Immunoassay System gave the following statistical data:
n
Range of
Observations
(µIU/mL) Intercept (µIU/mL) Slope
Correlation
Coefficient
(r)
59 2.5-100 0.53 1.03 0.988
DILUTION RECOVERY (LINEARITY)
Multiple volumetric dilutions of three samples containing various insulin levels with Access Ultrasensitive Insulin
Calibrator S0 (zero) resulted in the following data:
Sample 1
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
Neat N/A 258.0 N/A
1:1.4 184.0 184.0 100
1:2 129.0 126.0 97
1:4 64.5 61.7 96
1:8 32.3 36.3 112
1:16 16.1 16.7 104
Mean % Recovery 102
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Sample 2
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
Neat N/A 146.0 N/A
1:1.4 104.0 110.0 106
1:2 73.0 78.5 108
1:4 36.5 37.3 102
1:8 18.3 19.5 107
1:16 9.1 9.2 101
Mean % Recovery 105
Sample 3
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
Neat N/A 86.8 N/A
1:1.4 62.0 63.2 102
1:2 43.4 42.9 99
1:4 21.7 19.7 91
1:8 10.9 10.5 96
1:16 5.4 5.2 96
Mean % Recovery 97
SPIKING RECOVERY
Addition of four different levels of insulin to two serum samples with low insulin resulted in the following data:
Sample 1
(µIU/mL)
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
Neat N/A 11.5 N/A
5 16.5 15.8 96
50 61.5 57.0 92
100 112.0 105.0 94
220 232.0 242.0 104
Mean % Recovery 97
Sample 2
(µIU/mL)
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
Neat N/A 2.9 N/A
5 7.9 7.1 90
50 52.9 49.4 93
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Sample 2
(µIU/mL)
Expected Concentration
(µIU/mL)
Determined
Concentration (µIU/mL)
Recovery
(%)
100 103.0 105.0 102
220 223.0 199.0 89
Mean % Recovery 94
IMPRECISION
This assay exhibits total imprecision of less than 10% across the assay range. One study, performed by running three
replicates of each sample per assay and two assays per day provided the following data, analyzed via analysis of
variance (ANOVA).23,24
Control
Grand Mean (n=60)
(µIU/mL)
Within Run
(%CV)
Total Imprecision
(%CV)
1 0.15 4.2 5.6
2 0.30 2.7 4.0
3 0.93 2.6 4.5
4 12.90 2.0 3.5
5 37.40 2.0 3.3
6 99.30 2.1 3.1
ANALYTICAL SPECIFICITY / INTERFERENCES
Samples containing up to 10 mg/dL (171 µmol/L) bilirubin and lipemic samples containing the equivalent of 1,800 mg/dL
(20.32 mmol/L) triglycerides do not affect the concentration of insulin assayed. The addition of 5 g/dL of human albumin
to samples does not affect the concentration of insulin assayed.
Proinsulin and C-peptide were spiked into the S2 calibrator which contains 70 pmol/L (10 µIU/mL) insulin. Bovine and
porcine insulin were spiked into the zero calibrator. The following cross-reactivity data was obtained:
Substance
Analyte Added
(pmol/L) Cross-reactivity (%)
Proinsulin 4,000 -0.26
C-peptide 20,000 Not detectable
Bovine insulin 350 30
Porcine insulin 350 97
ANALYTICAL SENSITIVITY
The lowest detectable level of insulin distinguishable from zero (Access Ultrasensitive Insulin Calibrator S0) with 95%
confidence is 0.03 µIU/mL (0.21 pmol/L). This value is determined by processing a complete six point calibration curve,
controls, and ten replicates of the zero calibrator in multiple assays. The analytical sensitivity value is calculated from
the curve at the point that is two standard deviations from the mean measured zero calibrator signal.
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ADDITIONAL INFORMATION
Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are
trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.
* Lumi-Phos is a trademark of Lumigen, Inc., a subsidiary of Beckman Coulter, Inc.
SYMBOLS KEY
Glossary of Symbols is available at techdocs.beckmancoulter.com (document number C02724)
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Anti-Insulin Antibody (6E9F1)                                    
CATALOG NO: 
 
AMOUNT: 
 
IMMUNOGEN: 
 
CLONALITY: 
 
CLONE: 
 
HOST/ISOTYPE: 
 
PURIFICATION: 
 
FORM: 
 
CONCENTRATION: 
 
FORMULATION:   
                  
STORAGE CONDITIONS: 
 
 
SPECIFICITY: 
 
 
DESCRIPTION: 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
APPLICATION: 
 
 
 
 
 
 
 
A1364-1000          
 
1 mg 
 
Human recombinant Insulin expressed in yeast 
 
Monoclonal 
 
6E9F1 
 
Mouse IgG2a, κ 
 
Protein A purification 
 
Liquid 
 
0.5 mg/ml 
 
In PBS buffer, pH 7.4, containing 0.02% sodium azide 
 
For long term storage, aliquot and store at -20°C or below. Avoid 
repeated freezing and thawing cycles. 
 
Insulin Antibody (6E9F1) detects human Insulin and slightly 
recognizes proinsulin, it has no cross-reactivity with C-peptide. 
 
Insulin is one of the major regulatory hormones of intermediate 
metabolism throughout the body. It regulates the cellular uptake, 
utilization, and storage of glucose, amino acids, and fatty acids and 
inhibits the breakdown of glycogen, protein, and fat. Proinsulin is 
the prohormone precursor to insulin made in pancreas. It is 
processed by a series of proteases to form mature insulin. Mature 
insulin has 35 fewer amino acids; 4 are removed altogether, and 
the remaining 31 form the C-Peptide. The C-Peptide is abstracted 
from the center of the proinsulin sequence; the two other ends (α 
and β chains) remain connected by disulfide bonds. Deficiency of 
insulin results in diabetes mellitus, one of the leading causes of 
morbidity and mortality in the general population. Insulin is also 
present in tumors of B cell origin such as insulinoma. 
Insulin Antibody (6E9F1) is produced from the hybridoma resulting 
from fusion of SP2/0-Ag14 myeloma and B-lymphocytes obtained 
from mouse immunized with human recombinant Insulin expressed 
in yeast 
 
These antibodies are perfect choice for in vitro diagnostic assay 
development. They are prepared for non-clinical research use 
only. The recommended pairs are based on our R&D results. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Cross-reactivity of Insulin monoclonal antibodies by Indirect ELISA 
Assay protocol for sandwich ELISA: 
1. Microplate was coated with insulin, proinsulin or C-peptide respectively, followed by 3 
        washing cycles. 
2. Incubation with mouse anti-insulin antibody followed by 3 washing cycles. 
3. Incubation with goat anti-mouse lgG conjugated to peroxidase, followed by 3 washing 
cycles. 
4. Colorimetric determination of bound peroxidase activity. 
 
 
 
 
 
 
 
 
 
 
 
Assay protocol for Sandwich ELISA:  
1. Microplate was coated with a capture antibody against insulin, followed by 3 washing 
cycles.  
2. Incubation with insulin followed by 3 washing cycles.  
3. Incubation with peroxidase conjugated detection antibody against insulin, followed by 3 
washing cycles.  
4. Colorimetric determination of bound peroxidase activity. 
 
RELATED PRODUCTS: 
 ProInsulin (human) ELISA Kit (Cat. No. K7433) 
 Proinsulin Antibody (Clone HPI-B5) (Cat. No. 3106) 
 
 
 
FOR RESEARCH USE ONLY!  Not to be used on humans. 
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Anti-Insulin Antibody (5A6A4)                                    
CATALOG NO: 
 
AMOUNT: 
 
IMMUNOGEN: 
 
CLONALITY: 
 
CLONE: 
 
HOST/ISOTYPE: 
 
PURIFICATION: 
 
FORM: 
 
CONCENTRATION: 
 
FORMULATION:   
                  
STORAGE CONDITIONS: 
 
 
SPECIFICITY: 
 
 
DESCRIPTION: 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
APPLICATION: 
 
 
 
 
 
 
 
A1365-1000          
 
1 mg 
 
Human recombinant Insulin expressed in yeast 
 
Monoclonal 
 
5A6A4 
 
Mouse IgG2b, κ 
 
Protein A purification 
 
Liquid 
 
0.5 mg/ml 
 
In PBS buffer, pH 7.4, containing 0.02% sodium azide 
 
For long term storage, aliquot and store at -20°C or below. Avoid 
repeated freezing and thawing cycles. 
 
Insulin Antibody (5A6A4), mAb, Mouse detects human Insulin and 
it has no cross-reactivity with Proinsulin and C-peptide. 
 
Insulin is one of the major regulatory hormones of intermediate 
metabolism throughout the body. It regulates the cellular uptake, 
utilization, and storage of glucose, amino acids, and fatty acids and 
inhibits the breakdown of glycogen, protein, and fat. Proinsulin is 
the prohormone precursor to insulin made in pancreas. It is 
processed by a series of proteases to form mature insulin. Mature 
insulin has 35 fewer amino acids; 4 are removed altogether, and 
the remaining 31 form the C-Peptide. The C-Peptide is abstracted 
from the center of the proinsulin sequence; the two other ends (α 
and β chains) remain connected by disulfide bonds. Deficiency of 
insulin results in diabetes mellitus, one of the leading causes of 
morbidity and mortality in the general population. Insulin is also 
present in tumors of B cell origin such as insulinoma. 
Insulin Antibody (6E9F1) is produced from the hybridoma resulting 
from fusion of SP2/0-Ag14 myeloma and B-lymphocytes obtained 
from mouse immunized with human recombinant Insulin expressed 
in yeast 
 
These antibodies are perfect choice for in vitro diagnostic assay 
development. They are prepared for non-clinical research use 
only. The recommended pairs are based on our R&D results. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Cross-reactivity of Insulin monoclonal antibodies by Indirect ELISA 
Assay protocol for sandwich ELISA: 
1. Microplate was coated with insulin, proinsulin or C-peptide respectively, followed by 3 
        washing cycles. 
2. Incubation with mouse anti-insulin antibody followed by 3 washing cycles. 
3. Incubation with goat anti-mouse lgG conjugated to peroxidase, followed by 3 washing 
cycles. 
4. Colorimetric determination of bound peroxidase activity. 
 
 
 
 
 
 
 
 
 
 
 
Assay protocol for Sandwich ELISA:  
1. Microplate was coated with a capture antibody against insulin, followed by 3 washing 
cycles.  
2. Incubation with insulin followed by 3 washing cycles.  
3. Incubation with peroxidase conjugated detection antibody against insulin, followed by 3 
washing cycles.  
4. Colorimetric determination of bound peroxidase activity. 
 
RELATED PRODUCTS: 
 ProInsulin (human) ELISA Kit (Cat. No. K7433) 
 Proinsulin Antibody (Clone HPI-B5) (Cat. No. 3106) 
 
 
 
FOR RESEARCH USE ONLY!  Not to be used on humans. 
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Product name Recombinant human Insulin protein
Protein length Full length protein
Nature Recombinant
Source Escherichia coli
Accession P01308
Species Human
Sequence GIVEQCCTSIC SLYQLENYCN FVNQHL CGSHLVEALY
LVCGERGFFY TPKT
Molecular weight 6 kDa
Additional sequence information Recombinant Human Insulin produced in E. coli is a two chain, non-glycosylated polypeptide
chain containing 51 amino acids and having a molecular mass of 5.81 kDa.
Amino Acid Sequence
Biological activity ab123768 is fully biologically active when compared to World Health Organization (WHO)
reference standard which is 28 units/mg.
Applications Functional Studies
SDS-PAGE
HPLC
Purity > 98 % SDS-PAGE.
Purity is greater than 98% as determined by HPLC and SDS-PAGE. ab123768 is purified by
proprietary chromatographic techniques. Endotoxin Level: <0.1 ng/µg of Insulin.
Form Lyophilised
Product datasheet
Recombinant human Insulin protein ab123768
2 Abreviews
Overview
Description
Specifications
Our Abpromise guarantee covers the use of ab123768 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Preparation and Storage
1
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Stability and Storage Shipped at 4°C. Store at -20°C. Store under desiccating conditions.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Reconstitution Reconstitute in 5-10 mM HCl to a concentration of 1.0 mg/ml. The solution can then be diluted to
other aqueous buffers. Upon reconstitution ab123768 should be stored at 4°C for 2-7 days. For
long-term storage, it is recommended to add a carrier protein (0.1% HSA or BSA) and store
aliquots at –20°C or –70°C. Avoid freeze-thaw cycles.
Function Insulin decreases blood glucose concentration. It increases cell permeability to
monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate
cycle, and glycogen synthesis in liver.
Involvement in disease Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [MIM:176730].
Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [MIM:125852].
IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility
to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia
and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst.
These derangements result in long-term complications that affect the eyes, kidneys, nerves, and
blood vessels.
Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [MIM:606176].
PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus
type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first
months of life. Permanent neonatal diabetes requires lifelong therapy.
Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10)
[MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant
mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a
primary defect in insulin secretion and frequent insulin-independence at the beginning of the
disease.
Sequence similarities Belongs to the insulin family.
Cellular localization Secreted.
Preparation and Storage
General Info
Please note:  All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Our Abpromise to you: Quality guaranteed and expert technical support
Replacement or refund for products not performing as stated on the datasheet
Valid for 12 months from date of delivery
Response to your inquiry within 24 hours
We provide support in Chinese, English, French, German, Japanese and Spanish
Extensive multi-media technical resources to help you
We investigate all quality concerns to ensure our products perform to the highest standards
If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise,
please visit https://www.abcam.com/abpromise or contact our technical team.
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 Heraeus Deutschland GmbH & Co. KG  
Leverkusen    Number 81076212 
    Issue  2016-09-13 
1/2      1) Information on test methods is available on request.  
 
CLEVIOS™ PH 1000 
 
Description of Product Aqueous dispersion, blue liquid 
Synonyms / Abbreviations PEDT / PSS, PEDOT / PSS 
 ________________________________________________________________________________________ 
Physical Characteristics1) 
 
 Min  Max Unit 
Solid content 1.0 - 1.3 % 
Specific conductivity*        850   S/cm 
Viscosity        15 -    60 mPas 
*After the addition of 5% Dimethyl sulfoxide. Measured on the dried coating. 
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Mitsubushi Photopaper
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Applicable to: 370-0030   3 x Ab labelings (up to 20ug) 370-0005   1 x Ab labeling (up to 200µg)  
    370-0010   3 x Ab labelings (up to 200µg)  370-0015   1 x Ab labeling (up to 2mg)   Release 1 © EXPEDEON. 07/03/2018  
 
 
INTRODUCTION 
 
Lightning-Link® conjugation technology works by targeting amine 
groups (e.g. lysines) and is widely used to label antibodies.  
The Lightning-Link® Biotin kit allows Biotin conjugations to be set up 
in less than 30 seconds, simply by adding a solution of the antibody 
to a lyophilized mixture containing a proprietary activated Biotin 
ligand (Figure 1).  
 
 
 
 
 
 
Figure 1. Lightning-Link® antibody conjugation 
 
By circumventing the desalting or dialysis steps that commonly 
interrupt traditional antibody conjugation procedures, Lightning-
Link® technology can be used to label both small (e.g. 10 µg) and 
large quantities of primary antibodies with ease. Batch-to-batch 
variation upon scale up is minimal as the process is so simple, and 
recoveries are always 100%.  
Directly labeled primary antibodies are advantageous as they 
eliminate the need for secondary reagents in immunoassay 
procedures, thus removing a tedious extra cycle of incubation and 
wash steps in applications, such as ELISA and Western blotting.  
Lightning-Link® technology can also be used to label proteins, 
peptides and other biomolecules (See ‘the What can I label using 
Lightning-Link®?’ Section of the protocol for further information). 
 
KIT CONTENTS 
 
• 1 or 3 glass vial(s) of Lightning-Link® Rapid mix 
• 1 vial of LL Rapid Modifier reagent  
• 1 vial of LL Rapid Quencher reagent 
 
SHIPPING CONDITIONS 
 
The kit is shipped at ambient temperature in a tamper-evident 
polypropylene container. Store the kits at -20⁰ C upon receipt.  
 
Please note that the modifier and quencher FD after initial thawing 
can be stored at either 4⁰ C or -20⁰ C. 
 
 
 
 
 
BUFFER CONSIDERATIONS 
Please see the below table for recommended buffer conditions and 
components: 
Buffer Components  
pH 6.5-8.5 
Amine free buffer  
(e.g. MES, MOPS, HEPES, PBS) 
✓ 
Non-buffering salts 
 (e.g. sodium chloride) 
✓ 
Chelating agents 
(e.g.EDTA) 
✓ 
Sugars ✓ 
Glycerol <50% 
Thiomersal / Thimerosal  
Merthiolate  
Sodium Azide1 <0.1% 
BSA1,2 <0.1% 
Gelatin1,2 <0.1% 
Tris  <50mM 
Glycine  
Proclin  
Borate buffer ✓ 
Nucleophilic components 
(Primary amines e.g. amino acids or 
ethanolamine and thiols e.g. 
mercaptoethanol or DTT) 
 
1 Please note that individually the concentrations shown should not affect 
the reaction.  However in combination with additional compounds that are 
not recommended above a certain concentration, the reaction may be 
affected. 
2 If intending to use this kit for immunohistochemistry, it is recommended 
that there be no gelatin or BSA present.  
AMOUNT AND VOLUME OF ANTIBODY 
 
Prod. 
Code 
Recommend 
amount of 
antibody  
Maximum 
amount of 
antibody  
Maximum 
Conjugation 
volume 
370-0030 10µg 20µg 110µl 
370-0005 
370-0010 
100µg 200µg 100µl 
370-0015 1mg 2mg 1ml 
 
Superior conjugates are normally generated using the recommended 
amount of antibody. Using the maximum amount of antibody will still 
generate quality conjugates. 
 
Antibodies less than 1mg/ml can still be used to generate good 
conjugates provided the maximum conjugation volume is not 
exceeded. Adding less than the recommended maximum amount of 
antibody may result in unbound label post conjugation. This excess 
label will be deactivated by the quencher and removed during the first 
     Lightning-Link® Rapid Biotin Conjugation Kit (Type A*) 
*Optimized for assays using a streptavidin-labeled detection reagent 
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wash step of any application. We would recommend that antibodies 
below 0.5mg/ml are concentrated prior to use. 
Please contact our technical support team for more advice. 
INSTRUCTIONS 
Setting up your conjugation reaction 
1. Before you add antibody to the Lightning-Link® Rapid mix, add 
1µl of LL Rapid Modifier reagent for each 10 µl of antibody to be 
labeled. Mix gently.  
2. Remove the screw cap from the vial of Lightning-Link® Rapid 
mix and pipette the antibody sample (with added LL Rapid 
Modifier) directly onto the lyophilized material. Resuspend 
gently by withdrawing and re-dispensing the liquid once or 
twice using a pipette.  
3. Replace cap on the vial and leave standing for 15 minutes at 
room temperature (20-25ᴼC). Alternatively, and sometimes 
more conveniently, conjugations can be set up and left 
overnight at room temperature. Longer incubation times have 
no negative effect on the conjugation. 
4. After 15min incubation, add 1 µl of LL Rapid Quencher reagent 
for every 10 µl of antibody used. The conjugate can be used 
after 5 minutes. The conjugates do not require purification. 
STORAGE OF CONJUGATES 
 
Your biotin conjugate can be stored at 4⁰ C for up to 18 months.  For 
longer storage the conjugate can be stored at -20oC with a 
cryoprotectant such as 50% glycerol.  
The best storage conditions for any particular conjugate must be 
determined by experimentation.  
 
WHAT CAN I LABEL USING LIGHTNING-LINK®? 
 
Lightning-Link® technology works by targeting free amine groups. It 
can be used to label antibodies, peptides, proteins and other 
molecules with free amine groups. 
The protocol provided here is optimized for labeling IgGs, when 
labeling other molecules please contact our technical support team 
at: www.expedeon.com/contact/   
 
Our custom conjugation service team will also be happy to generate 
your conjugate for you. Please contact our sales team for a quote. 
www.expedeon.com/contact/  
WHAT IF MY BUFFER DOESN’T FIT THE 
REQUIREMENTS? 
 
The AbSelect™ purification kit range allows you to quickly and simply 
purify your antibody using our conjugation friendly buffers. 
The appropriate kit to use depends on your particular sample. Please 
view our AbSelect ™ range of products on our website to select the 
best kit. 
 
If your antibody is already purified but its concentration is too low, you 
can concentrate it by using our AbSelect™ Antibody Concentration 
and Clean Up Kit (product code 861-0010).  This kit can also be used 
to remove low molecular weight contaminants such as azide, Tris or 
glycine.  
If your antibody contains BSA, you can use our AbSelect™  BSA 
removal kit (product code 820-0100) to purify your antibody in one 
simple step.  
Our AbSelect™ kits are fully compatible with Lightning-Link® and are 
designed to work with IgG antibodies. The only exception is the 
Concentration and Clean Up kit (product code 861-0010) which will 
work with any molecule greater than 10kDa. 
 
TECHNICAL SUPPORT 
For technical enquiries get in touch with our technical support team 
at:  www.expedeon.com/contact/   
 
 
 
 
 
 
 
 
Limited use license  
 
Expedeon’s products are offered for research purposes alone, and are not 
intended for human, therapeutic or diagnostic use. The purchase of this 
product conveys to the buyer (whether the buyer is a not-for-profit, academic 
or for-profit entity) the non-transferable right to use the amount of product 
purchased and the components of the product for in-house research. The 
buyer shall not sell or otherwise transfer this product, its components, or 
materials prepared therefrom to any third party. The buyer shall not use this 
product or its components for commercial purposes. For the avoidance of 
doubt, ‘commercial purposes’ means any activity by a party for consideration 
and includes, without limitation, use of the product or its components (i) in the 
manufacturing of other materials (ii) to provide a service, information or data, 
(iii) for therapeutic, diagnostic or prophylactic purposes, or (iv) for 
repackaging/resale, whether or not such product or its components are resold 
for use in research. The use of this product by the buyer constitutes agreement 
with the terms of this limited use label.  
Many of Expedeon’s products and technologies are protected by patents or are 
the subject of patent filings. For information on purchasing a license for 
commercial use please contact us at +44 (0) 1223 873364 
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ab154873
Gold Conjugation Kit 
(40nm, 20OD)
Instructions for Use
For the Covalent Conjugation of Antibodies or 
Proteins to Gold
This product is for research use only and is not 
intended for diagnostic use.
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1. Introduction
Abcam’s Gold Conjugation Kit allows antibodies or proteins to be 
covalently attached to ultra-stable Gold nanoparticles at very high 
OD quickly and easily. The hands-on time for the Gold conjugation 
procedure is about 2 minutes and the conjugate is ready to use 
within 15 minutes. 
The Gold nanoparticles in this kit are supplied as a freeze dried 
mixture. The conjugation reaction is initiated simply by adding a 
solution of the antibody, which becomes attached (via lysine 
residues) to the gold surface.
 The resulting covalent conjugates are more stable than those 
prepared by passive adsorption methods. Moreover, unlike passive 
methods, the coating procedure is not dependent on the isoelectric 
point of the antibody, and extensive trials at different pH values are 
not required; all antibodies react at a single fixed pH.
The 3 and 10 test Conjugation Kits are designed to label 12 µl per 
vial.
The 1 test Conjugation Kit is designed to label 120 µl per vial.
3
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2. Kit Contents 
Amount
Components
3 Tests 10 Tests 1 Test
Amount of Antibody/Test 12 µl 12 µl 120 µl
Storage
Gold Reaction Buffer 1 vial 1 vial 1 vial -20°C
Gold Antibody Diluent 1 vial 1 vial 1 vial -20°C
Gold 3 vials 10 vials 1 vial -20°C
Gold Quencher 1 vial 1 vial 1 vial -20°C
3. Storage and Handling
For storage temperatures please see the Table
For handling refer to Safety Datasheet
4
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4. Additional Materials
Microfuge Tubes (0.5 or 1.5 ml)
Microfuge
5. General Guidelines 
A. Prior to Labeling
 Antibody must be purified
 Avoid amino acids (e.g. glycine)
 Avoid other primary amines (e.g. Tris)
 Avoid thiols (e.g. mercaptoethanol, DTT)
 Avoid carboxylic acids (e.g. EDTA)
Stock antibodies at concentrations of >1mg/ml are 
recommended; as this allows potentially interfering substances 
in the antibody preparation to be diluted out (see Step 6.2). You 
should pay particular attention to the composition of the stock 
antibody if you require less than a 1 in 5 dilution in step 6.2 of 
the protocol. If you are in any doubt about the suitability of 
buffers/additives in your preparation of antibody please contact 
our technical team for advice.
The kit is compatible with PBS, MES, MOPS, HEPES, sugars, 
salts and detergents.
5
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B. Amount of Antibody
The optimum amount of antibody (which will influence the 
number of antibody molecules per particle) may be application-
dependent and you may need to conjugate different amounts of 
antibody to optimize your assay. The initial amount of antibody 
recommended corresponds to 10 µg antibody per ml of 10 OD 
gold, which is about half of that normally used for passive                     
(non-covalent) conjugations. However lower or higher 
concentrations can be explored as there is no risk of aggregation 
because of the protective surface coating. 
6. Labeling Protocol
Note: The following protocol is for 1 vial from the 3 or 10 test 
Conjugation Kit.  Adjust volumes as required for the larger 
1 test Conjugation Kit.
1. Allow all of the reagents to warm to room temperature.
2. Dilute your stock antibody with the  Gold antibody diluent 
provided in the kit to 0.1 mg/ml.
Note: If you wish to examine the effect of varying the 
amount of antibody, make additional stocks at 0.05 and 
0.2 mg/ml in the first instance. Do not change the volume of 
antibody added in order to vary the amount of antibody 
added, you must change the concentration of the stock 
antibody and use a fixed volume.
6
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3. For each reaction:  In a clean 0.5 ml or 1.5 ml microfuge 
tube add 42 µl of Gold reaction buffer and then 12 µl of your 
diluted antibody from Step.2. Mix thoroughly.
(Note: 420 µl Gold reaction buffer and 120 µl antibody for 
large volume kit).
4. Transfer 45 µl of the mixture to a vial of Gold. Reconstitute 
the freeze dried mixture by gently pipetting up and down. 
Allow to stand at room temperature for 15 minutes.
(Note: 450 µl Gold for large volume kit). 
5. Add 5 µl of EL Gold Quencher and mix gently. You now 
have 50 µl of 20 OD conjugate. Dilute further as required for 
your application. 
(Note: 50 µl Gold Quencher for large volume kit – final 
volume 500 µl of 20 OD conjugate).
Note: For a conjugate 100% free from unbound antibody we
recommend washing the particles and adding 10 times the 
volume of the quencher diluted 1:10 in water to the 
conjugate (i.e. 1ml 1:10 diluted quencher to 100µl of 
conjugate) and then centrifuge it in a microfuge at 9,000 g 
10 minutes. Carefully remove the supernatant, gently tap the 
pellet and add the quencher diluted 1:10 in water for long 
term storage in the fridge (up to 1 year) or 1:10 diluted 
quencher with addition of 0.5 - 2% BSA for LFA or your 
preferred buffer.
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Note: While you should avoid thiols (e.g. DTT or 
mercaptoethanol) the other interfering substances noted in 
section 5 have no negative effect once the conjugate has 
been formed.
Gold Labeled antibody should be stored at +4°C
7. Frequently Asked Questions
What can I do if my antibody preparation contains interfering 
substances?
The simplest procedure is to dialyse the antibody against a suitable 
buffer. Relatively weak buffers (e.g. 20mM) are preferred so that the 
pH conditions of the covalent reaction are not significantly altered 
upon addition of the antibody. See also the comments in Section 5 of 
the protocol. If dialysis is not practical you can use other popular 
methods of buffer exchange if required e.g. desalting columns.
Does the antibody bind to the metal surface?
No. The protective surface coat completely shields the metal surface 
and prevents direct metal-antibody interactions. For this reason, you 
cannot use Gold Conjugation Kits for passive conjugation of 
antibodies.
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Can antibodies from different species be used?
Yes, the system has been tested with antibodies from a variety of 
species including mouse, rabbit, goat and sheep. 
What type of linkage to gold is formed?  
The antibody becomes covalently and irreversibly attached via lysine 
residues to the GOLD surface.
Can antibody fragments be conjugated?
Yes. One of the advantages of the protective coat is that it is less 
likely than a bare metal surface to cause denaturation and loss of 
affinity of the antibody fragments.
What if I need bulk material?
The kit that you have purchased is a convenience product for rapid 
production of small quantities of conjugate for screening purposes. 
Abcam offers the kit in a range of sizes. Please enquire.
Is the kit suitable for conjugating analytes and other small 
molecules?
Yes, but please contact technical services. Depending on the 
functional groups on your analyte you may need a different type of 
surface or different chemistry for optimal results.
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Puriﬁed Streptavidin (280302)
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Purified Streptavidin 
  
  
 Catalog# / Size 280302 / 250 µg 
Ave. Rating ★★★★★ 0 reviews 
Description Streptavidin is a 52.8 kD tetrameric protein obtained from Streptomyces avidinii. It binds to 
biotin with a very high affinity and is one of the strongest interactions in nature with a 
dissociation constant of 10  mol/L. It is used in a wide range of applications including 
ELISA, flow cytometry, molecular biology, and bionanotechnology.
-14
Product Details 
Formulation Phosphate-buffered solution containing 0.09% sodium azide. 
Concentration 1.0 mg/ml 
Storage & Handling Store between 2°C and 8°C. 
Application FC - Quality tested
ELISA Capture, ELISA Detection, IF, IHC-F, IHC-P, IP, WB - Reported in the literature
Recommended Usage To coat one 96-well plate dilute 24 µl of Purified Streptavidin into 11.976ml of 1X Coating 
Buffer (Cat# 421701, Coating Buffer 5X concentrate). Final concentration in the coated plate is 
2 µg/ml. This recommendation is to perform the protocol for HLA class I ELISA to evaluate Flex-
T™ peptide exchange. For other applications the reagent needs to be optimized.
Antigen Details 
Structure 52.8 kD tetrameric protein. 
Distribution Streptavidin binds to biotin with high affinity. 
Ligand Receptor Biotin. 
Antigen References 1. Dundas CM, et al. 2013. Appl. Microbiol. Biotechnol. 97:9343.
2. Zhao X, et al. 2013. J. Anal. Methods Chem. 2013:581093. 
3. Kaplan DL, et al. 1999. Biomol. Eng. 16:135.
4. Wilbur DS, et al. 1999. Biomol. Eng. 16:113.
5. Sano T, et al. 1998. J. Chromatogr. B. Biomed. Sci. Appl. 715:85.
Related Protocols 
Flex-T™ HLA Class I ELISA Protocol 
Cell Surface Immunofluorescence Staining Protocol 
For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other 
violations that may occur with the use of our products.
 
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, 
www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to 
manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written 
approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. 
Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or 
commercial use.
 
BioLegend Inc., 9727 Pacific Heights Blvd, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587
Version: 2    Revision Date: 10/19/2016 
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www.roche-applied-science.com
For life science research only. Not for use in diagnostic 
procedures.
Bovine Serum Albumin, Fraction V
Lyophilizate
Cat. No. 10 735 078 001 50 g y Version 08
Cat. No. 10 735 086 001 100 g Content version: March 2013
Cat. No. 10 735 094 001 500 g
Cat. No. 10 735 108 001 1 kg Store at +2 to +8°C
1. What this Product Does
Contents
Lyophilizate
Storage and Stability
The lyophilizate is stable at +2 to +8°C until the expiration date printed
on the label.
Application
• Buffer component (in immunochemistry, biochemistry, cell biology,
molecular biology)
• Reducing agent
• Protein blocker (saturation of all protein binding sites in ELISAs,
Southern blots and western blots)
• Stabilizer
• Media supplement (for media that require addition of protein)
• Carrier protein
• Standard protein (gel electrophoresis, protein determination)
2. Additional Information on this Product
Solubility 
Albumin is readily soluble at concentrations of 50 – 100 mg/ml. To pre-
vent foaming, always use gentle stirring to dissolve the protein. Adding
a non-ionic detergent to the solution will also minimize its tendency to
foam. 
Appearance 
Albumin solutions can vary from colorless to light yellow or light
greenish-yellow; the color of the solution does not affect its function.
Molecular weight
68,000 Da (583 amino acids; see Ref. 3 for amino acid sequence)
pH
7.0 ± 0.2
Ligand binding
Albumin binds many substances reversibly and therefore can serve as
a transport or carrier protein in the body. The most important function
of albumin in the body is the transport of lipids and free fatty acids.
The ligand binding properties of albumin serves two purposes in the
laboratory. On the one hand it can release bound components into the
reaction mixture, while on the other hand it can adsorb impurities from
the medium. Since albumin binds many anions and cations, it can also
be used in ion binding studies.
The affinity of albumin for ligands depends on the hydrophobic char-
acter of the molecules and their charge. Molecules with long alkyl
chains and negatively charged groups are bound very firmly, while
molecules with short chains and positively charged groups are bound
less firmly (1). Ligands that are bound by albumin include fatty acids,
cationic and neutral detergents, acetylcholine, ascorbic acid, penicillin,
thyroxin, digitonin, hormones, metal ions, bilirubin, sugars and drugs
(2). 
Analysis
References
1 Spector, A.A. et al. (1971) Biochemistry 10, 3229.
2 Skipski, V.P. (1972) in: Blood Lipids and Lipoproteins: Quantita-
tion, Composition and Metabolism (Nelson, G.J., ed.). New York, 
Wiley-Interscience, pp. 471–583.
3 Hirayama, K. Akashi, S., Furuya, M. & Fukuhara, K. (1990) 
Biochem. Biophys. Res. Commun. 173, 639.
Albumin 98% (gel electroph.)
Protein 95%
H2O 5%
Sodium (flame photometry) 0.5%
Potassium (flame photometry) 0.006%
Lithium (flame photometry) 0.0003%
Calcium (o-cresolphthalein) 0.02%
Magnesium (xylidyl blue) 0.003%
Heavy metals (as Pb) 0.003%
Iron (bathophenanthraline) 0.001%
P (inorganic) 0.002%
Chloride (mercurom.) 0.15%
Glucose (enzym.) 0.05%
Glycerol (enzym.) 0.005%
L-Lactate (enzym.) 0.1%
Microorganisms 100 organism/g
0313.11743899001
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Supertex inc.
Supertex inc.
 www.supertex.com
Doc.# DSFP-LND150    
C041114
LND150
General Description
The LND150 is a high voltage N-channel depletion mode 
(normally-on) transistor utilizing Supertex’s lateral DMOS 
technology. The gate is ESD protected. 
The LND150 is ideal for high voltage applications in the 
areas of normally-on switches, precision constant current 
sources, voltage ramp generation and amplification.
N-Channel Depletion-Mode
DMOS FET
Absolute Maximum Ratings 
Parameter Value
Drain-to-source BVDSX
Drain-to-gate BVDGX 
Gate-to-source ±20V
Operating and storage temperature -55OC to +150OC
Absolute Maximum Ratings are those values beyond which damage to the device may 
occur. Functional operation under these conditions is not implied. Continuous operation 
of the device at the absolute rating level may affect device reliability. All voltages are 
referenced to device ground.
TO-92
Product Marking
TO-243AA (SOT-89)
LN1EW  W = Code for Week Sealed 
              = “Green” Packaging 
Features
►    Free from secondary breakdown
►    Low power drive requirement
►    Ease of paralleling
►    Excellent thermal stability
►    Integral source-drain diode
►    High input impedance and low CISS
►    ESD gate protection
Applications
 ► Solid state relays
 ► Normally-on switches
 ► Converters
 ► Power supply circuits
 ► Constant current sources
 ► Input protection circuits 
GATE
SOURCE
DRAIN
TO-243AA (SOT-89)
GATE
SOURCE
DRAIN
SOURCE
YY = Year Sealed 
WW = Week Sealed 
             = “Green” Packaging 
SiLN 
D 1 5 0  
Y Y W W  
TO-92
Packages may or may not include the following marks: Si or
Pin Configuration 
TO-236AB (SOT-23)
TO-236AB (SOT-23)
DRAIN
SOURCE
GATE
NDEW  W = Code for Week Sealed 
              = “Green” Packaging 
Product Summary
BVDSX/BVDGX
(V)
RDS(ON)
(max)
IDSS
(min)
500 1.0kΩ 1.0mA
Ordering Information
Part Number Package Options Packing
LND150K1-G TO-236AB (SOT-23) 3000/Reel
LND150N3-G TO-92 1000/Bag
LND150N3-G P002 TO-92 2000/Reel
LND150N3-G P003 TO-92 2000/Reel
LND150N3-G P005 TO-92 2000/Reel
LND150N3-G P013 TO-92 2000/Reel
LND150N3-G P014 TO-92 2000/Reel
LND150N8-G TO-243AA (SOT-89) 2000/Reel
-G denotes a lead (Pb)-free / RoHS compliant package
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LND150
Electrical Characteristics (TA = 25OC unless otherwise specified)
Sym Parameter Min Typ Max Units Conditions
BVDSX Drain-to-source breakdown voltage 500 - - V VGS = -10V, ID = 1.0mA
VGS(OFF) Gate-to-source off voltage -1.0 - -3.0 V VGS = 25V, ID = 100nA
ΔVGS(OFF) Change in VGS(OFF) with temperature - - 5.0 mV/OC VGS = 25V, ID = 100nA
IGSS Gate body leakage current - - 100 nA VGS = ± 20V, VDS = 0V
ID(OFF) Drain-to-source leakage current
- - 100 nA VGS = -10V, VDS = 450V
- - 100 µA VDS = 0.8V Max Rating, VGS = -10V, TA = 125OC
IDSS Saturated drain-to-source current 1.0 - 3.0 mA VGS = 0V, VDS = 25V
RDS(ON) Static drain-to-source on-state resistance - 850 1000 Ω VGS = 0V, ID = 0.5mA
ΔRDS(ON) Change in RDS(ON) with temperature - - 1.2 %/OC VGS = 0V, ID = 0.5mA
GFS Forward transductance 1.0 2.0 -   m                VDS = 0V, ID = 1.0mA
CISS Input capacitance - 7.5 10
pF
VGS = -10V, 
VDS = 25V, 
f = 1.0MHz
COSS Common source output capacitance - 2.0 3.5
CRSS Reverse transfer capacitance - 0.5 1.0
td(ON) Turn-on delay time - 0.09 -
µs
VDD = 25V,
ID = 1.0mA,
RGEN = 25Ω
t
r
Rise time - 0.45 -
td(OFF) Turn-off delay time - 0.1 -
tf Fall time - 1.3 -
VSD Diode forward voltage drop - - 0.9 V VGS = -10V, ISD = 1.0mA
t
rr
Reverse recovery time - 200 - ns VGS = -10V, ISD = 1.0mA
Notes:
1. All D.C. parameters 100% tested at 25OC unless otherwise stated. (Pulse test: 300µs pulse, 2% duty cycle.)
2. All A.C. parameters sample tested.
Notes:
†   ID (continuous) is limited by max rated Tj.
Thermal Characteristics
Package
ID
(continuous)†
(mA)
ID
(pulsed)
(mA)
Power Dissipation
@TA = 25OC(W)
θja
(OC/W)
IDR
(mA)
IDRM†
(mA)
TO-236AB (SOT-23) 13 30 0.36 203 13 30
TO-92 30 30 0.74 132 30 30
TO-243AA (SOT-89) 30 30 1.6‡ 133 30 30
Switching Waveforms and Test Circuit
90%
10%
90% 90%
10%10%
Pulse
Generator
VDD
RL
OUTPUT
D.U.T.
t(ON)
td(ON)
t(OFF)
td(OFF)tr
INPUT
INPUT
OUTPUT
0V
VDD
RGEN
0V
-10V
tf
Ω
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LND150
Typical Performance Curves
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LND150
Typical Performance Curves (cont.)
Gate Drive Dynamic Characteristics
VGS(OFF) and RDS Variation with TemperatureTransfer Characteristics
Capacitance vs. Drain-to-Source Voltage
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% Final Matlab Script
% This section provids the graphs for the Antibody Pairing tests
CAP1364 = xlsread('CapA1364.xlsx','A2:D16');    % Read Data
Cap1364conc = CAP1364(:,1);                     % Allocate Variables
Cap1364odmean = CAP1364(:,2);                   % Allocate Variables
Cap1364odmax = CAP1364(:,3);                    % Allocate Variables
Cap1364odmin = CAP1364(:,4);                    % Allocate Variables
CAP1365 = xlsread('CapA1365.xlsx','A2:D16');    % Read Data
Cap1365conc = CAP1365(:,1);                     % Allocate Variables
Cap1365odmean = CAP1365(:,2);                   % Allocate Variables
Cap1365odmax = CAP1365(:,3);                    % Allocate Variables
Cap1365odmin = CAP1365(:,4);                    % Allocate Variables
figure      % New Figure
semilogx(Cap1364conc,Cap1364odmean,'b'); hold on;
semilogx(Cap1364conc,Cap1364odmax,'r.',Cap1364conc,Cap1364odmin,'r.');
for i = 1:1:15
    semilogx([Cap1364conc(i) Cap1364conc(i)], [Cap1364odmin(i)
 Cap1364odmax(i)],'r','MarkerSize',10); hold on
end
xlabel('Insulin Concentration (ng/mL)');
ylabel('OD 450nM');
title('ELISA results Capture A1364');
grid on;
set(gcf,'color','white')
figure      % New Figure
semilogx(Cap1365conc,Cap1365odmean,'b'); hold on;
semilogx(Cap1365conc,Cap1365odmax,'r.',Cap1365conc,Cap1365odmin,'r.');
for i = 1:1:15
    semilogx([Cap1365conc(i) Cap1365conc(i)], [Cap1365odmin(i)
 Cap1365odmax(i)],'r','MarkerSize',10); hold on
end
xlabel('Insulin Concentration (ng/mL)');
ylabel('OD 450nM');
title('ELISA results Capture A1365');
grid on;
set(gcf,'color','white')
% This section generates the OEC Output Graphs (Id vs Vds)
outputo = dlmread('OECT_output_404.lvm'); % Read OECT Data
outputm = dlmread('OECT_output_306.lvm'); % Read MOSFET Data
oVgg = outputo(:, 1);           % Channel 1 ADC Input
oVgs = outputo(:, 2);           % Channel 2 ADC Input
oVdd = outputo(:, 3);           % Channel 3 ADC Input
oVds = outputo(:, 4);           % Channel 4 ADC Input
oVsd = -oVds;                   % Allocate Variables
oVsg = -oVgs;                   % Allocate Variables
mVgg = outputm(:, 1);           % Channel 1 ADC Input
1
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mVgs = outputm(:, 2);           % Channel 2 ADC Input
mVdd = outputm(:, 3);           % Channel 3 ADC Input
mVds = outputm(:, 4);           % Channel 4 ADC Input
mVsd = -mVds;                   % Allocate Variables
mVsg = -mVgs;                   % Allocate Variables
oN = 0:1:length(oVgg)-1;        % Number of samples
mN = 0:1:length(mVgg)-1;        % Number of samples
Rd = 147;                       % Drain Resistor Value (Ohm)
Rg = 148;                       % Gate Resistor Value (Ohm)
oId = (oVds - oVdd)/Rd;         % OECT Drain Current Formula
mId = (mVdd - mVds)/Rd;         % MOSFET Drain Current Formula
oNGV = 12;
oipt = findchangepts(oVgg, 'MaxNumChanges', oNGV);  % Detect Falling
 Edges
mNGV = 9;
mipt = findchangepts(mVgg, 'MaxNumChanges', mNGV);  % Detect Falling
 Edges
odiff = (oipt(2)-oipt(1))/2;
mdiff = (mipt(2)-mipt(1))/2;
for i = 1:1:(oNGV-4) % OECT Array Development
    oVddArrayForward(i,:) = oVdd(oipt(i):100:oipt(i) + odiff);
    oVdsArrayForward(i,:) = oVds(oipt(i):100:oipt(i) + odiff);
    oIdArrayForward(i,:) = oId(oipt(i):100:oipt(i) + odiff);
end
for l = 1:1:(mNGV-1) % MOSFET Array Development
    mVddArrayForward(l,:) = mVdd(mipt(l):100:mipt(l) + mdiff);
    mVdsArrayForward(l,:) = mVds(mipt(l):100:mipt(l) + mdiff);
    mIdArrayForward(l,:) = mId(mipt(l):100:mipt(l) + mdiff);
end
for k = 1:1:(oNGV-4)
   IdArrayFull(i,:) =  oId(oipt(i):oipt(i+1));
   VddArrayFull(i,:) =  oVdd(oipt(i):oipt(i+1));
   VdsArrayFull(i,:) =  oVds(oipt(i):oipt(i+1));
end
% Plot the OECT output characteristics Id vs Vds
figure
set(gcf,'color','white');
for i = (oNGV-4):-1:1
    plot(oVdsArrayForward(i,:),oIdArrayForward(i,:)*1000); hold on;
end
xlabel('V_{DS} (V)');
ylabel('I_{D} (mA)');
title('Output Characteristics: OECT');
title(legend,'V_{G}');
legend('0.40 V','0.45 V','0.50 V','0.55 V','0.60 V','0.65 V','0.70
 V','0.75 V','Location','northeast');
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set(gca, 'xdir','reverse');
axis([-0.8 0 0 4 ]);
% Plot the MOSFET output characteristics Id vs Vdd
figure      % New Figure
set(gcf,'color','white');
for i = (mNGV-2):-1:1
    plot(mVddArrayForward(i,:),mIdArrayForward(i,:)*1000); hold on;
end
xlabel('V_{D} (V)');
ylabel('I_{D} (mA)');
title('Output Characteristics: LND150');
title(legend,'V_{G}');
legend('0.60 V','0.40 V','0.20 V','0 V','-0.20 V','-0.40 V','-0.60
 V','Location','northwest'); % '-0.80 V',
% set(gca, 'ydir','reverse');
axis([0 4 0 3.5 ]);
% Plot the OECT output characteristics Id vs Vds
figure      % New Figure
set(gcf,'color','white');
for i = (oNGV-4):-1:2
    plot(oVddArrayForward(i,:),oIdArrayForward(i,:)*1000); hold on;
end
xlabel('V_{DD} (V)');
ylabel('I_{D} (mA)');
title('Output Characteristics: OECT');
title(legend,'V_{G}');
legend('0.40 V','0.45 V','0.50 V','0.55 V','0.60 V','0.65 V','0.70
 V','Location','northwest'); %
set(gca, 'xdir','reverse');
axis([-0.8 0 0 3.5 ]);
% Plot the OECT Hysteresis output characteristics Id vs Vds
figure      % New Figure
set(gcf,'color','white');
% plot(oVds(32188:80:288868),oId(32188:80:288868)*1000);
for i = (oNGV-4):-1:2
    plot(oVds(oipt(i):80:oipt(i+1)-1),oId(oipt(i):80:oipt(i
+1)-1)*1000);hold on;
end
xlabel('V_{DS} (V)');
ylabel('I_{D} (mA)');
title('Output: Hysteresis Id vs Vds');
set(gca, 'xdir','reverse');
title(legend,'V_{G}');
legend('0.40 V','0.45 V','0.50 V','0.55 V','0.60 V','0.65 V','0.70
 V','Location','northeast');
axis([-0.8 0 0 4 ]);
xarrow1 = [0.36 0.37];
yarrow1 = [0.7 0.71];
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annotation('textarrow',xarrow1,yarrow1,'Color','b');
xarrow2 = [0.41 0.4];
yarrow2 = [0.65 0.644];
annotation('textarrow',xarrow2,yarrow2,'Color','b');
% Plot the Transfer and Transconductance Characteristics (Id vs Vg)
transfer1 = dlmread('OECT_transfer_28.lvm'); % Read Data
transfer2 = dlmread('OECT_transfer_40.lvm'); % Read Dara
tVgg1 = transfer1(:, 1);        % Channel 1 ADC Input
tVgs1 = transfer1(:, 2);        % Channel 2 ADC Input
tVdd1 = transfer1(:, 3);        % Channel 3 ADC Input
tVds1 = transfer1(:, 4);        % Channel 4 ADC Input
tVsd1 = -tVds1;                 % Allocate Variables
tVsg1 = -tVgs1;                 % Allocate Variables
tVgg2 = transfer2(:, 1);        % Channel 1 ADC Input
tVgs2 = transfer2(:, 2);        % Channel 2 ADC Input
tVdd2 = transfer2(:, 3);        % Channel 3 ADC Input
tVds2 = transfer2(:, 4);        % Channel 4 ADC Input
tVsd2 = -tVds2;                 % Allocate Variables
tVsg2 = -tVgs2;                 % Allocate Variables
tN1 = 0:1:length(tVgg1)-1;      % Number of samples
tN2 = 0:1:length(tVgg2)-1;      % Number of samples
Rd = 147;                       % Drain Resistor Value (Ohm)
Rg = 148;                       % Gate Resistor Value (Ohm)
tId1 = (tVds1 - tVdd1)/Rd;      % Drain Current Formula
tIg1 = (tVgg1 - tVgs1)/Rg;      % Gate Current Formula
tId2 = (tVds2 - tVdd2)/Rd;      % Drain Current Formula
tIg2 = (tVgg2 - tVgs2)/Rg;      % Gate Current Formula
% Transconductance Calculations
startrange = 50000;   % Startrange = 400;
endrange = 225000;     % Endrange = 820;
order = 9;          % Polynomial order
fit1 = 0;
fit2 = 0;
Fit_array1 =
 polyfit(tVsg1(startrange:endrange),tId1(startrange:endrange),order);
Fit_array2 =
 polyfit(tVsg2(startrange:endrange),tId2(startrange:endrange),order);
h = 0.001;
xVsg1 = tVsg1(startrange):h:tVsg1(endrange);
xVsg2 = tVsg2(startrange):h:tVsg2(endrange);
for i = 1:order+1
   fit1 = fit1 + Fit_array1(i)*xVsg1.^((order+1) - i);
   fit2 = fit2 + Fit_array2(i)*xVsg2.^((order+1) - i);
end
gm1 = diff(fit1);   % Transconductance
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gm2 = diff(fit2);   % Transconductance
%Plot the Transfer curves Id vs Time
figure      % New Figure
set(gcf,'color','white');
yyaxis left
plot(-xVsg1(420:1000),fit1(1,420:1000)*1000);
xlabel('V_{G} (V)');
ylabel('I_{D} (mA)');
title('Transfer: Transfer curve and resulting transconductance');
axis([0.1 0.7 0 2.5 ]);
xarrow1 = [0.25 0.2];
yarrow1 = [0.75 0.75];
annotation('textarrow',xarrow1,yarrow1,'Color','blue');
yyaxis right
plot(-xVsg1(420:1000),gm1(420:1000)*1000000);
ylabel('g_{m} (mS)');
axis([0.1 0.7 0 7 ]);
xarrow2 = [0.75 0.80];
yarrow2 = [0.7 0.7];
annotation('textarrow',xarrow2,yarrow2,'Color','red');
figure      % New Figure
set(gcf,'color','white');
plot(-xVsg1(420:1000),gm1(1,420:1000)*1000000); hold on
plot(-xVsg2(420:1000),gm2(1,420:1000)*1000000);
plot([0.3 0.3],[0 6],'k--','MarkerSize',7);
axis([0.1 0.7 0 7 ]);
xlabel('V_{G} (V)');
ylabel('g_{m} (mS)');
title('Transfer: Shift in Transconductance');
legend('PBS','500 ng/mL Insulin');
% Plot the Time dependant Characteristics (Id vs Time)
response = dlmread('OECT_response_13.lvm'); % Read Data
rVgg = response(:, 1);          % Channel 1 ADC Input
rVgs = response(:, 2);          % Channel 2 ADC Input
rVdd = response(:, 3);          % Channel 3 ADC Input
rVds = response(:, 4);          % Channel 4 ADC Input
rVsd = -rVds;                   % Allocate Variables
rVsg = -rVgs;                   % Allocate Variables
time = (1:15:length(rVgg))/15;
const(1,1:length(time)) = 1.926;
Rd = 147;                       % Drain Resistor Value (Ohm)
Rg = 148;                       % Gate Resistor Value (Ohm)
rId = (rVds - rVdd)/Rd;         % Drain Current Formula
rIg = (rVgg - rVgs)/Rg;         % Gate Current Formula
figure      % New Figure
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set(gcf,'color','white');
plot(time,rId(1:15:450)*1000); hold on;
plot(time,const,'k--');
xlabel('Time (s)');
ylabel('I_{D} (mA)');
legend('Response At Biased Point','Settling point = 1.926 mA');
title('Response: Id vs Time');
axis([0 30 1.9 2.35 ]);
% Plot the Current Differences between various concentrations
CurrConc = xlsread('test_list.xlsx',5,'A1:B28');    % Read Data
Averages = xlsread('test_list.xlsx',5,'D1:E7');     % Read Data
best = xlsread('test_list.xlsx',5,'H1:I7');         % Read Data
Conc = CurrConc(:,1);           % Allocate Variables
Curr = CurrConc(:,2)/1000;      % Allocate Variables
ConcAvg = Averages(:,1);        % Allocate Variables
Avg = Averages(:,2)/1000;       % Allocate Variables
bestx = best(:,1);              % Allocate Variables
besty = best(:,2)/1000;         % Allocate Variables
figure      % New Figure
set(gcf,'color','white');
loglog(ConcAvg, Avg,'b-'); hold on
for i = 1:4:28
        loglog(Conc(i:i+3,1), Curr(i:i+3,1),'r-');
        loglog(Conc(i:i+3,1), Curr(i:i+3,1),'r.','MarkerSize',9);
end
grid on;
xlabel('Insulin Concentration (ng/mL)');
ylabel('I_{D} (mA)');
figure      % New Figure
set(gcf,'color','white');
loglog(bestx, besty,'b-'); hold on
loglog(bestx, besty,'r.','MarkerSize',9);
grid on;
xlabel('Insulin Concentration (ng/mL)');
ylabel('I_{D} (mA)');
axis([0 2000 0 2.6 ]);
% Plot Multiple Transfer Graphs (Id vs Vds)
transfer1 = dlmread('OECT_transfer_53.lvm'); % Read Data
transfer2 = dlmread('OECT_transfer_54.lvm'); % Read Data
transfer3 = dlmread('OECT_transfer_55.lvm'); % Read Data
transfer4 = dlmread('OECT_transfer_56.lvm'); % Read Data
start = 50000;
step = 1000;
stop = 225000;
Vgg1 = transfer1(start:step:stop, 1);       % Channel 1 ADC Input
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Vgs1 = transfer1(start:step:stop, 2);       % Channel 2 ADC Input
Vdd1 = transfer1(start:step:stop, 3);       % Channel 3 ADC Input
Vds1 = transfer1(start:step:stop, 4);       % Channel 4 ADC Input
Vsd1 = -Vds1;                               % Allocate Variables
Vsg1 = -Vgs1;                               % Allocate Variables
Vgg2 = transfer2(start:step:stop, 1);       % Channel 1 ADC Input
Vgs2 = transfer2(start:step:stop, 2);       % Channel 2 ADC Input
Vdd2 = transfer2(start:step:stop, 3);       % Channel 3 ADC Input
Vds2 = transfer2(start:step:stop, 4);       % Channel 4 ADC Input
Vsd2 = -Vds2;                               % Allocate Variables
Vsg2 = -Vgs2;                               % Allocate Variables
Vgg3 = transfer3(start:step:stop, 1);       % Channel 1 ADC Input
Vgs3 = transfer3(start:step:stop, 2);       % Channel 2 ADC Input
Vdd3 = transfer3(start:step:stop, 3);       % Channel 3 ADC Input
Vds3 = transfer3(start:step:stop, 4);       % Channel 4 ADC Input
Vsd3 = -Vds3;                               % Allocate Variables
Vsg3 = -Vgs3;                               % Allocate Variables
Vgg4 = transfer4(start:step:stop, 1);       % Channel 1 ADC Input
Vgs4 = transfer4(start:step:stop, 2);       % Channel 2 ADC Input
Vdd4 = transfer4(start:step:stop, 3);       % Channel 3 ADC Input
Vds4 = transfer4(start:step:stop, 4);       % Channel 4 ADC Input
Vsd4 = -Vds4;                               % Allocate Variables
Vsg4 = -Vgs4;                               % Allocate Variables
n = length(Vgg1);               % Number of samples
N = 0:1:length(Vgg1)-1;         % Samples Vector
Rd = 147;                       % Drain Resistor Value (Ohm)
Rg = 148;                       % Gate Resistor Value (Ohm)
Id1 = (Vds1 - Vdd1)/Rd;        % Drain Current Formula for OECT 1
Ig1 = (Vgg1 - Vgs1)/Rg;        % Gate Current Formula for OECT 1
Id2 = (Vds2 - Vdd2)/Rd;        % Drain Current Formula for OECT 2
Ig2 = (Vgg2 - Vgs2)/Rg;        % Gate Current Formula for OECT 2
Id3 = (Vds3 - Vdd3)/Rd;        % Drain Current Formula for OECT 3
Ig3 = (Vgg3 - Vgs3)/Rg;        % Gate Current Formula for OECT 3
Id4 = (Vds4 - Vdd4)/Rd;        % Drain Current Formula for OECT 4
Ig4 = (Vgg4 - Vgs4)/Rg;        % Gate Current Formula for OECT 4
IdAverage = (Id1 + Id2 + Id3 + Id4)/4;
figure      % New Figure
set(gcf,'color','white');
plot(Vgg1,Id1*1000); hold on;   % Multiply with 1000 to get in mA
plot(Vgg2,Id2*1000);            % Multiply with 1000 to get in mA
plot(Vgg3,Id3*1000);            % Multiply with 1000 to get in mA
plot(Vgg4,Id4*1000);            % Multiply with 1000 to get in mA
plot(Vgg1,IdAverage*1000);      % Multiply with 1000 to get in mA
xlabel('V_{G} (V)');
ylabel('I_{D} (mA)');
title('Transfer: I_{D} vs V_{G}');
legend('OECT 1','OECT 2','OECT 3','OECT 4');
axis([0 1 0 2.5 ]);
Published with MATLAB® R2018a
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